A Phase 2/3 interventional study of Immune Globulin Intravenous (Human), 10% in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 9 sites in United States. Open to participants aged 24 Months and older. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 11th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2/3, and was the 6th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 24 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 21 · Phase 4 3
First in 2000; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 26 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
23 studies in Primary Immunodeficiency Diseases by Takeda: 2 open now, 3 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2007, is one of 5 in phase 2/3, and was the 3rd registered.
Takeda’s Primary Immunodeficiency Diseases studies by the year they started, since 2002.
2 of the studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, from their registry updates:
Among Takeda’s 23 in Primary Immunodeficiency Diseases:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the tolerability of IGIV, 10% given subcutaneously and the pharmacokinetics of immunoglobulin G (IgG) following subcutaneous (SC) treatment with IGIV, 10% in subjects with primary immunodeficiency (PID) disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part 3b), Expressed as a Percentage
Expressed as (AUC_SC/AUC_IV) \* 100
Time frame: Week 12 (IV) and week 32 or 33 (SC)
Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10%, in Participants Aged 2 to <12 Years.
Administration of IGIV, 10%: - Part 1 = IV administration (IV) - Parts 2, 3a, 3b = SC administration (SC)
Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visits 1, and 5 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; and at the end-of-study evaluation
Percentage of Participants in Full Safety Data Set (FSDS) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
Time frame: Throughout study (1 year and 9 months)
Percentage of Participants Naïve to SC Administration of Immunoglobulins (SNSC) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped.
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
Time frame: Throughout study (1 year and 9 months)
Percentage of Participants With Prior Experience With Subcutaneous Administration of Immunoglobulins (SESC) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
Time frame: Throughout study (1 year and 9 months)
Percentage of Infusions in FSDS for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
Time frame: Throughout study (1 year and 9 months)
Percentage of Infusions in SNSC for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
Time frame: Throughout study (1 year and 9 months)
Percentage of Infusions in SESC for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
Time frame: Throughout study (1 year and 9 months)
Study Part 1 (IV): Maximum Plasma Concentration (C-max)
Maximal immune globulin concentration after infusion
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.
Study Part 1 (IV): Minimum Plasma Concentration (C-min)
Minimal immune globulin concentration after infusion
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.
Study Part 1 (IV): Weight-adjusted Clearance
Computed as weight-adjusted dose divided by total AUC
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.
Study Part 1 (IV): Terminal Half-life
Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of immunoglobulin in the body to be reduced by 50%during the terminal phase.
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.
Study Part 2 (Subcutaneous (SC)): Maximum Plasma Concentration (C-max)
Maximal immune globulin concentration after infusion
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Study Part 2 (SC): Time to Maximum Immune Globulin Concentration (T-max)
Time to reach C-max
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Study Part 2 (SC): Minimum Plasma Concentration (C-min)
Minimal immune globulin concentration after infusion
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Study Part 2 (SC): Weight-adjusted Clearance
Computed as weight-adjusted dose divided by total AUC
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Study Part 3B: Maximum Plasma Concentration (C-max)
Maximal immune globulin concentration after infusion
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Study Part 3B: Time to Maximum Immune Globulin Concentration (T-max)
Time to reach C-max
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Study Part 3B: Minimum Plasma Concentration (C-min)
Minimal immune globulin concentration after infusion
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Study Part 3B: Area Under the Curve (AUC)
The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Study Parts 1, 2 and 3b, AUC(0-τ) was standardized for the infusion intervals (3 or 4 weeks vs. 1 week).
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Study Part 3B: Weight-adjusted Clearance
Computed as weight-adjusted dose divided by total AUC
Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Trough Levels of IgG After Administration of IGIV, 10%, in Participants 12 Years and Older
Part 1: IgG trough levels measured at each IV infusion day (every 3rd or 4th week depending on schedule/frequency of participants for a total of 12 weeks) Part 2: IgG trough levels measured at weeks 1, 5 and 9 (of a total of 12 weeks) Part 3a: IgG trough levels measured at weeks 1 and 5 (of a total of 6 weeks) Part 3b: IgG trough levels measured at weeks 1, 5, 9 and 12 (of a total of 12 weeks)
Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visits 1, and 5 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; and at the end-of-study evaluation
Trough Levels of Antibody to Haemophilus Influenzae In All Study Participants
Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.
Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation
Trough Levels of Antibody to Hepatitis B in All Study Participants
Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.
Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation
Trough Levels of Antibody to Tetanus In All Study Participants
Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.
Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation
Number of Anti-Measles Antibody Titers That Were Below or Above the Protective Titer Level
Antibody Titers That Were Below or Above the Protective Titer Level of \>1:8 for IV and SC Treatment in Study Parts 1, 2, 3a and 3b. Participants had multiple anti-measles antibody titers measured during the study.
Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation
Annual Infection Rates During Treatment
Annual rate of all infections calculated using a Poisson model to account for different lengths of observation per subject using SAS V9.1.3 procedure GENMOD with allowance for overdispersion by deviance method. Point estimates and likelihood-ratio based 95% confidence intervals were provided. Infections as included in analysis comprised all reported AEs that were coded to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of infections and infestations, described as an infection by investigator, or for which anti-infective medication was prescribed.
Time frame: Throughout the study, 1 year and 9 months
Annual Rate of Acute Serious Bacterial Infections During IV and SC Treatment (FSDS)
Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per subject using SAS V9.1.3 procedure GENMOD with an allowance for overdispersion by the deviance method.
Time frame: Throughout the study, 1 year and 9 months
Rate of Temporally Associated AEs Per Infusion
Rate of AEs per infusion defined as the total number of all AEs that begin during infusion or within 72 hours of completion of an infusion ("temporally associated") divided by the total number of infusions.
Time frame: During Infusion or Within 72 Hours of Completion of Infusions
AEs Deemed/Judged to be Related by the Investigator
Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug that occur at any time during the study divided by the total number of infusions.
Time frame: Throughout the study period (1 year and 9 months)
Frequency of Dose Adjustments (If IgG Trough Levels <4.5 g/L)
Frequency of Dose Adjustments Based on IgG Trough Levels \<4.5 g/L IgG, if Any, for Each Study Part. Defined/calculated as the number of participants requiring dose adjustments divided by the number of participants, for each respective data set.
Time frame: Throughout the study period (1 year and 9 months)
Proportion of Participants Reporting ≥1 Temporally Associated Moderate or Severe AEs
Proportion of Participants Reporting 1 or More Moderate or Severe AEs That Begin During Infusion or Within 72 Hours of Completion of an Infusion.
Time frame: During Infusion or Within 72 Hours of Completion of Infusions
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (FSDS)
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR
Time frame: Throughout entire study (1 year and 9 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (FSDS)
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.
Time frame: Throughout entire study (1 year and 9 months)
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SNSC -All Ages)
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR
Time frame: Throughout entire study (1 year and 9 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SNSC- All Ages)
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.
Time frame: Throughout entire study (1 year and 9 months)
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SESC)
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR
Time frame: Throughout entire study (1 year and 9 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SESC)
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.
Time frame: Throughout entire study (1 year and 9 months)
Percentage of Infusions Associated With ≥1 AE Related to the Study Drug
Time frame: Throughout the study period (1 year and 9 months)
Percentage of Infusions Associated With ≥1 AEs That Begin During Infusion or Within 72 Hours of Completion of Infusion
Time frame: During Infusion or Within 72 Hours of Completion of Infusions
Percentage of Infusions Associated With ≥1 AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Time frame: During Infusion or Within 72 Hours of Completion of Infusions
Percentage of Infusions Associated With ≥1 Systemic AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Time frame: During Infusion or Within 72 Hours of Completion of Infusions
Percentage of Infusions Associated With ≥1 Local AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Time frame: During Infusion or Within 72 Hours of Completion of Infusions
Recruitment was conducted in the United States at 9 study sites.
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 14 | 35 |
| Completed | 13 | 35 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 13 | 35 |
| Completed | 12 | 32 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Family emergency | 0 | 1 |
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 12 | 32 |
| Completed | 12 | 32 |
| Not completed | 0 | 0 |
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 12 | 32 |
| Completed | 12 | 32 |
| Not completed | 0 | 0 |
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 10 | 26 |
| Completed | 9 | 25 |
| Not completed | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Expressed as (AUC_SC/AUC_IV) \* 100
| percent | Participants ≥12 Years Old With PK Data Part 1 and Part 3b |
|---|---|
| Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part 3b), Expressed as a Percentage | 95.2 (92.3 to 98.2) |
Administration of IGIV, 10%: - Part 1 = IV administration (IV) - Parts 2, 3a, 3b = SC administration (SC)
| g/L | Participants Aged 2 to <12 Years |
|---|---|
| Part 1 (IV), Screening visit (n=14) | 11.400 (9.640 to 16.800) |
| Part 1 (IV), 3 week Interval, Visit 1 (n=5) | 10.100 (NA to NA) |
| Part 1 (IV), 3 week Interval, Visit 2 (n=4) | 11.500 (NA to NA) |
| Part 1 (IV), 3 week Interval, Visit 3 (n=5) | 10.600 (NA to NA) |
| Part 1 (IV), 3 week Interval, Visit 4 (n=5) | 10.100 (NA to NA) |
| Part 1 (IV), 3 week Interval, Visit 5 (n=5) | 10.800 (NA to NA) |
| Part 1 (IV), 4 week Interval, Visit 1 (n=7) | 9.640 (7.240 to 17.400) |
| Part 1 (IV), 4 week Interval, Visit 2 (n=9) | 10.000 (7.230 to 12.400) |
| Part 1 (IV), 4 week Interval, Visit 3 (n=7) | 9.080 (6.340 to 18.500) |
| Part 1 (IV), 4 week Interval, Visit 4 (n=8) | 10.500 (7.420 to 17.800) |
| Part 2 (SC), Visit 1 (n=12) | 13.650 (12.300 to 16.700) |
| Part 2 (SC), Visit 5 (n=12) | 12.800 (11.200 to 16.500) |
| Part 2 (SC), Visit 9 (n=12) | 13.600 (10.100 to 17.100) |
| Part 3a (SC), Visit 1 (n=11) | 11.200 (10.300 to 19.100) |
| Part 3a (SC), Visit 5 (n=11) | 12.200 (11.500 to 20.000) |
| Part 3b (SC), Visit 1 (n=12) | 11.500 (9.170 to 15.800) |
| Part 3b (SC), Visit 5 (n=12) | 12.600 (10.200 to 15.200) |
| Part 3b (SC), Visit 9 (n=12) | 12.800 (10.300 to 15.900) |
| End of Study (n=13) | 12.300 (8.570 to 18.000) |
Maximal immune globulin concentration after infusion
| g/L | 12 Years and Older |
|---|---|
| Study Part 1 (IV): Maximum Plasma Concentration (C-max) | 22.7 (21.0 to 25.0) |
Minimal immune globulin concentration after infusion
| g/L | 12 Years and Older |
|---|---|
| Study Part 1 (IV): Minimum Plasma Concentration (C-min) | 10.1 (9.4 to 12.4) |
Computed as weight-adjusted dose divided by total AUC
| mL/kg/day | 12 Years and Older |
|---|---|
| Study Part 1 (IV): Weight-adjusted Clearance | 1.36 (1.23 to 1.42) |
Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of immunoglobulin in the body to be reduced by 50%during the terminal phase.
| days | 12 Years and Older |
|---|---|
| Study Part 1 (IV): Terminal Half-life | 33.1 (28.7 to 41.4) |
Maximal immune globulin concentration after infusion
| g/L | 12 Years and Older |
|---|---|
| Study Part 2 (Subcutaneous (SC)): Maximum Plasma Concentration (C-max) | 14.5 (12.3 to 16.4) |
Time to reach C-max
| days | 12 Years and Older |
|---|---|
| Study Part 2 (SC): Time to Maximum Immune Globulin Concentration (T-max) | 4.8 (3.0 to 4.9) |
Minimal immune globulin concentration after infusion
| g/L | 12 Years and Older |
|---|---|
| Study Part 2 (SC): Minimum Plasma Concentration (C-min) | 12.5 (11.3 to 14.2) |
Computed as weight-adjusted dose divided by total AUC
| mL/kg/day | 12 Years and Older |
|---|---|
| Study Part 2 (SC): Weight-adjusted Clearance | 1.86 (1.61 to 2.04) |
Maximal immune globulin concentration after infusion
| g/L | 12 Years and Older |
|---|---|
| Study Part 3B: Maximum Plasma Concentration (C-max) | 14.1 (12.5 to 16.3) |
Time to reach C-max
| days | 12 Years and Older |
|---|---|
| Study Part 3B: Time to Maximum Immune Globulin Concentration (T-max) | 2.9 (1.2 to 3.2) |
Minimal immune globulin concentration after infusion
| g/L | 12 Years and Older |
|---|---|
| Study Part 3B: Minimum Plasma Concentration (C-min) | 12.6 (10.6 to 14.0) |
The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Study Parts 1, 2 and 3b, AUC(0-τ) was standardized for the infusion intervals (3 or 4 weeks vs. 1 week).
| g*days/L | 12 Years and Older |
|---|---|
| Study Part 3B: Area Under the Curve (AUC) | 94.6 (80.4 to 106.9) |
Computed as weight-adjusted dose divided by total AUC
| mL/kg/day | 12 Years and Older |
|---|---|
| Study Part 3B: Weight-adjusted Clearance | 2.00 (1.84 to 2.12) |
Part 1: IgG trough levels measured at each IV infusion day (every 3rd or 4th week depending on schedule/frequency of participants for a total of 12 weeks) Part 2: IgG trough levels measured at weeks 1, 5 and 9 (of a total of 12 weeks) Part 3a: IgG trough levels measured at weeks 1 and 5 (of a total of 6 weeks) Part 3b: IgG trough levels measured at weeks 1, 5, 9 and 12 (of a total of 12 weeks)
| g/L | 12 Years and Older |
|---|---|
| Part 1, Screening visit (n=35) | 11.800 (10.300 to 13.000) |
| Part 1, 3 week Interval, Visit 1 (n=4) | 10.900 (NA to NA) |
| Part 1, 3 week Interval, Visit 2 (n=4) | 11.050 (NA to NA) |
| Part 1, 3 week Interval, Visit 3 (n=5) | 14.000 (NA to NA) |
| Part 1, 3 week Interval, Visit 4 (n=5) | 11.700 (NA to NA) |
| Part 1, 3 week Interval, Visit 5 (n=5) | 12.400 (NA to NA) |
| Part 1, 4 week Interval, Visit 1 (n=29) | 11.000 (10.000 to 12.300) |
| Part 1, 4 week Interval, Visit 2 (n=29) | 10.800 (9.650 to 12.500) |
| Part 1, 4 week Interval, Visit 3 (n=30) | 10.200 (9.480 to 12.600) |
| Part 1, 4 week Interval, Visit 4 (n=30) | 10.150 (9.480 to 12.200) |
| Part 2, Visit 1 (n=35) | 15.300 (14.800 to 17.100) |
| Part 2, Visit 5 (n=34) | 12.700 (11.600 to 15.200) |
| Part 2, Visit 9 (n=32) | 12.900 (11.800 to 14.800) |
| Part 3a, Visit 1 (n=32) | 12.850 (11.600 to 14.900) |
| Part 3a, Visit 5 (n=31) | 13.100 (11.400 to 15.100) |
| Part 3b, Visit 1 (n=31) | 12.900 (11.600 to 15.200) |
| Part 3b, Visit 5 (n=28) | 13.400 (11.000 to 14.600) |
| Part 3b, Visit 9 (n=31) | 13.600 (11.000 to 14.400) |
| End of Study (n=34) | 13.100 (11.300 to 14.400) |
Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.
| µg/mL | All Participants |
|---|---|
| Part 1, Screening visit (n=49) | 2.790 (2.300 to 3.240) |
| Part 1, 3 week Interval, Visit 1 (n=10) | 2.830 (2.020 to 4.350) |
| Part 1, 3 week Interval, Visit 2 (n=10) | 2.885 (1.910 to 4.310) |
| Part 1, 3 week Interval, Visit 3 (n=10) | 3.150 (2.030 to 3.950) |
| Part 1, 3 week Interval, Visit 4 (n=10) | 3.145 (0.820 to 4.040) |
| Part 1, 3 week Interval, Visit 5 (n=10) | 3.045 (1.650 to 4.140) |
| Part 1, 4 week Interval, Visit 1 (n=38) | 2.210 (1.860 to 2.480) |
| Part 1, 4 week Interval, Visit 2 (n=39) | 2.030 (1.680 to 2.780) |
| Part 1, 4 week Interval, Visit 3 (n=39) | 2.130 (1.750 to 2.670) |
| Part 1, 4 week Interval, Visit 4 (n=38) | 2.135 (2.020 to 2.610) |
| Part 2, Visit 1 (n=47) | 3.280 (3.000 to 3.860) |
| Part 2, Visit 5 (n=46) | 2.810 (2.360 to 3.080) |
| Part 2, Visit 9 (n=44) | 3.175 (2.530 to 3.470) |
| Part 3a, Visit 1 (n=44) | 2.840 (2.400 to 3.160) |
| Part 3b, Visit 1 (n=43) | 3.030 (2.610 to 3.500) |
| Part 3b, Visit 5 (n=41) | 3.070 (2.820 to 3.650) |
| Part 3b, Visit 9 (n=44) | 3.285 (2.780 to 3.870) |
| Extension, Visit 1 (n=36) | 2.940 (2.530 to 3.780) |
| End of Study (n=46) | 3.010 (2.660 to 3.690) |
Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.
| mIU/mL | All Participants |
|---|---|
| Part 1, Screening visit (n=36) | 239.450 (180.000 to 293.300) |
| Part 1, 3 week Interval, Visit 1 (n=8) | 182.050 (139.500 to 789.000) |
| Part 1, 3 week Interval, Visit 2 (n=10) | 251.150 (208.600 to 311.900) |
| Part 1, 3 week Interval, Visit 3 (n=10) | 282.050 (231.900 to 333.900) |
| Part 1, 3 week Interval, Visit 4 (n=10) | 274.200 (223.100 to 460.700) |
| Part 1, 3 week Interval, Visit 5 (n=10) | 261.850 (233.900 to 292.400) |
| Part 1, 4 week Interval, Visit 1 (n=36) | 197.750 (135.600 to 242.200) |
| Part 1, 4 week Interval, Visit 2 (n=39) | 213.600 (191.000 to 282.500) |
| Part 1, 4 week Interval, Visit 3 (n=39) | 202.800 (172.200 to 262.600) |
| Part 1, 4 week Interval, Visit 4 (n=38) | 207.850 (183.800 to 265.800) |
| Part 2, Visit 1 (n=46) | 401.350 (380.800 to 482.200) |
| Part 2, Visit 5 (n=46) | 341.100 (301.700 to 364.700) |
| Part 2, Visit 9 (n=44) | 316.800 (282.800 to 367.900) |
| Part 3a, Visit 1 (n=44) | 318.450 (280.200 to 351.000) |
| Part 3b, Visit 1 (n=43) | 385.200 (304.300 to 454.300) |
| Part 3b, Visit 5 (n=41) | 314.100 (247.200 to 374.900) |
| Part 3b, Visit 9 (n=44) | 351.050 (292.000 to 412.200) |
| Extension, Visit 1 (n=36) | 328.750 (273.100 to 368.400) |
| End of Study (n=44) | 319.600 (297.000 to 372.400) |
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
| Percentage of Participants | Infusion Rate Change - For Any Reason | Infusion Rate Change - For Tolerability/AE |
|---|---|---|
| Study Part 1 (IV) (n= 49) | 18.4 | 16.3 |
| Study Part 2 (SC) (n= 47) | 29.8 | 4.3 |
| Study Part 3A (SC) (n=44) | 15.9 | 2.3 |
| Study Part 3B (SC) (n=44) | 13.6 | 2.3 |
| Study Extension (SC) (n= 36) | 13.9 | 0.0 |
| Study Part 2, 3A, 3B, Study Extension (n= 47) | 40.4 | 4.3 |
Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.
| IU/mL | All Participants |
|---|---|
| Part 1, Screening visit (n=49) | 2.840 (2.500 to 3.660) |
| Part 1, 3 week Interval, Visit 1 (n=10) | 3.010 (1.740 to 3.640) |
| Part 1, 3 week Interval, Visit 2 (n=10) | 3.500 (1.970 to 4.640) |
| Part 1, 3 week Interval, Visit 3 (n=10) | 3.360 (2.180 to 4.540) |
| Part 1, 3 week Interval, Visit 4 (n=10) | 3.205 (1.810 to 5.030) |
| Part 1, 3 week Interval, Visit 5 (n=10) | 3.520 (2.230 to 4.220) |
| Part 1, 4 week Interval, Visit 1 (n=37) | 2.340 (1.980 to 2.830) |
| Part 1, 4 week Interval, Visit 2 (n=39) | 2.360 (1.880 to 2.760) |
| Part 1, 4 week Interval, Visit 3 (n=38) | 2.125 (1.890 to 2.680) |
| Part 1, 4 week Interval, Visit 4 (n=36) | 2.325 (1.910 to 2.800) |
| Part 2, Visit 1 (n=47) | 4.310 (3.890 to 5.050) |
| Part 2, Visit 5 (n=46) | 3.445 (2.920 to 4.030) |
| Part 2, Visit 9 (n=43) | 3.720 (3.090 to 4.160) |
| Part 3a, Visit 1 (n=44) | 3.090 (2.670 to 3.830) |
| Part 3b, Visit 1 (n=43) | 3.690 (3.210 to 4.220) |
| Part 3b, Visit 5 (n=41) | 3.410 (2.780 to 4.440) |
| Part 3b, Visit 9 (n=43) | 3.150 (2.920 to 3.920) |
| Extension, Visit 1 (n=36) | 3.355 (2.440 to 4.480) |
| End of Study (n=46) | 3.860 (3.150 to 5.000) |
Antibody Titers That Were Below or Above the Protective Titer Level of \>1:8 for IV and SC Treatment in Study Parts 1, 2, 3a and 3b. Participants had multiple anti-measles antibody titers measured during the study.
| Antibody titers | Full Safety Data Set |
|---|---|
| Anti-Measles Antibody Tests Below a Titer of >1:8 | 0 |
| Anti-Measles Antibody Tests Above a Titer of >1:8 | 654 |
Annual rate of all infections calculated using a Poisson model to account for different lengths of observation per subject using SAS V9.1.3 procedure GENMOD with allowance for overdispersion by deviance method. Point estimates and likelihood-ratio based 95% confidence intervals were provided. Infections as included in analysis comprised all reported AEs that were coded to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of infections and infestations, described as an infection by investigator, or for which anti-infective medication was prescribed.
| Estimated infections per year | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Study Part 1 (IV) | 5.0 (2.3 to 9.3) | 5.2 (3.6 to 7.2) |
| Study Part 2 (SC) | 5.6 (2.7 to 10.0) | 4.1 (2.6 to 6.1) |
| Study Part 3A (SC) | 3.5 (1.4 to 7.1) | 4.6 (2.6 to 7.3) |
| Study Part 3B (SC) | 3.9 (1.6 to 7.8) | 3.8 (2.4 to 5.8) |
| Study Extension (SC) | 4.0 (2.4 to 6.2) | 3.8 (2.6 to 5.3) |
| Study Part 2, 3A, 3B, Study Extension (all SC) | 4.3 (2.8 to 6.4) | 4.0 (3.0 to 5.2) |
Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per subject using SAS V9.1.3 procedure GENMOD with an allowance for overdispersion by the deviance method.
| Estimated infections/year | IV Treatment | All SC Treatment Periods |
|---|---|---|
| Annual Rate of Acute Serious Bacterial Infections During IV and SC Treatment (FSDS) | 0.000 | 0.067 |
Rate of AEs per infusion defined as the total number of all AEs that begin during infusion or within 72 hours of completion of an infusion ("temporally associated") divided by the total number of infusions.
| AEs per infusion | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) (Units Analyzed N= 207, 162, 45) | 0.25 | 0.45 | 0.00 |
| Study Part 2 (SC) (N = 595, 469, 126) | 0.08 | 0.13 | 0.08 |
| Study Part 3a (SC) (N = 268, 206, 62) | 0.00 | 0.08 | 0.00 |
| Study Part 3b (SC) (N = 538, 418, 120) | 0.08 | 0.08 | 0.00 |
| Study Extension (SC) (N = 893, 664, 229) | 0.07 | 0.09 | 0.00 |
| Total SC (N = 2294, 1757, 537) | 0.08 | 0.08 | 0.00 |
Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug that occur at any time during the study divided by the total number of infusions.
| AEs per infusion | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) (Units Analyzed N= 207, 162, 45) | 0.00 | 0.25 | 0.00 |
| Study Part 2 (SC) (N = 595, 469, 126) | 0.07 | 0.06 | 0.08 |
| Study Part 3a (SC) (N = 268, 206, 62) | 0.00 | 0.00 | 0.00 |
| Study Part 3b (SC) (N = 538, 418, 120) | 0.00 | 0.00 | 0.00 |
| Study Extension (SC) (N = 893, 664, 229) | 0.00 | 0.03 | 0.00 |
| Total SC (Study Parts 2, 3A, 3B, Study Extension) | 0.00 | 0.00 | 0.00 |
Frequency of Dose Adjustments Based on IgG Trough Levels \<4.5 g/L IgG, if Any, for Each Study Part. Defined/calculated as the number of participants requiring dose adjustments divided by the number of participants, for each respective data set.
| ratio | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) | 0.00 | 0.00 | 0.00 |
| Study Part 2 (SC) | 0.00 | 0.00 | 0.00 |
| Study Part 3a (SC) | 0.00 | 0.00 | 0.00 |
| Study Part 3b (SC) | 0.00 | 0.00 | 0.00 |
| Study Extension (SC) | 0.00 | 0.00 | 0.00 |
| Total SC (Study Parts 2, 3A, 3B, Study Extension) | 0.00 | 0.00 | 0.00 |
Proportion of Participants Reporting 1 or More Moderate or Severe AEs That Begin During Infusion or Within 72 Hours of Completion of an Infusion.
| Proportion of participants | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) | 0.43 | 0.47 | 0.27 |
| Study Part 2 (SC) | 0.36 | 0.44 | 0.09 |
| Study Part 3a (SC) | 0.23 | 0.24 | 0.20 |
| Study Part 3b (SC) | 0.36 | 0.38 | 0.30 |
| Study Extension (SC) | 0.50 | 0.56 | 0.33 |
| Total SC (Study Parts 2, 3A, 3B, Study Extension) | 0.66 | 0.75 | 0.36 |
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
| Percentage of Participants | Infusion Rate Change - For Any Reason | Infusion Rate Change - For Tolerability/AE |
|---|---|---|
| Study Part 1 (IV) (n= 38) | 23.7 | 21.1 |
| Study Part 2 (SC) (n= 36) | 33.3 | 5.6 |
| Study Part 3A (SC) (n=34) | 20.6 | 2.9 |
| Study Part 3B (SC) (n=34) | 17.6 | 2.9 |
| Study Extension (SC) (n= 27) | 14.8 | 0.0 |
| Study Part 2, 3A, 3B, Study Extension (n= 36) | 47.2 | 5.6 |
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR
| Adverse events | Study Part 1, IV Administration | Study Part 2, SC Administration | Study Part 3a, SC Administration | Study Part 3b, SC Administration | Study Extension, SC Administration | Total SC (Parts 2, 3a, 3b, Extension) |
|---|---|---|---|---|---|---|
| Abdominal Discomfort- non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 3 | 3 |
| Abdominal Distension-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 7 | 7 |
| Abdominal Distension-non-SAE, NR, Moderate | 0 | 0 | 0 | 2 | 2 | 4 |
| Abdominal Distension-non-SAE, R, Mild | 0 | 1 | 0 | 1 | 0 | 2 |
| Abdominal Distension-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Abdominal Pain-non-SAE, NR, Mild | 1 | 0 | 1 | 0 | 1 | 2 |
| Abdominal Pain-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 6 | 6 |
| Abdominal Pain Upper-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 2 | 2 |
| Abdominal Pain Upper-non-SAE, R, Mild | 0 | 3 | 1 | 0 | 0 | 4 |
| Abdominal Tenderness-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Acne-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Acne-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Acute Sinusitis-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Addison's Disease-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Addison's Disease-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Alopecia-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Ammonia Increased-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Animal Bite-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Anorexia-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Anxiety-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Aphthous Stomatitis-non-SAE, NR, Mild | 0 | 1 | 1 | 0 | 2 | 4 |
| Arthralgia-non-SAE, NR, Moderate | 0 | 3 | 1 | 2 | 1 | 7 |
| Arthralgia-non-SAE, NR, Severe | 0 | 0 | 0 | 0 | 1 | 1 |
| Arthralgia-non-SAE, R, Mild | 1 | 0 | 1 | 0 | 0 | 1 |
| Arthralgia-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Arthritis-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Arthropod Bite-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 1 | 2 |
| Asthenia-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Asthenia-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Asthma-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Asthma-non-SAE, NR, Moderate | 3 | 0 | 1 | 1 | 3 | 5 |
| Asthma-non-SAE, NR, Severe | 0 | 0 | 0 | 1 | 0 | 1 |
| Asthma-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Asthma Exercise Induced-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| ADHD-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Back Pain-non-SAE, NR, Mild | 1 | 0 | 0 | 2 | 0 | 2 |
| Back Pain-non-SAE, NR, Moderate | 1 | 0 | 0 | 2 | 0 | 2 |
| Back Pain-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Biliary Tract Infection Bacterial-SAE, NR, Moderat | 0 | 1 | 0 | 0 | 0 | 1 |
| Blepharitis-non-SAE,NR, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Blepharitis-non-SAE,NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| B.P. Diastolic Decreased-non-SAE, R, Mild | 0 | 0 | 2 | 0 | 0 | 2 |
| Blood Pressure Increased-non-SAE, NR, Mild | 0 | 0 | 0 | 2 | 0 | 2 |
| Blood Pressure Increased-non-SAE, R, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| B.P. Systolic Increased-non-SAE, NR, Mild | 0 | 1 | 1 | 0 | 0 | 2 |
| B.P. Systolic Increased-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| B.P. Systolic Increased-non-SAE, R, Mild | 1 | 4 | 2 | 0 | 0 | 6 |
| B.P. Systolic Increased-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Breast Tenderness-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Breath Sounds Abnormal-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Bronchitis-non-SAE, NR, Mild | 1 | 1 | 0 | 2 | 2 | 5 |
| Bronchitis-non-SAE, NR, Moderate | 1 | 0 | 1 | 0 | 4 | 5 |
| Bursitis-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Candidiasis-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Cardiac Murmur-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Centrl Venous Catheterisation-non-SAE, NR, Moderat | 0 | 0 | 0 | 0 | 1 | 1 |
| Cervical Spinal Stenosis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Chest Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Chest Pain-SAE, NR, Severe | 0 | 0 | 0 | 1 | 0 | 1 |
| Chills-non-SAE, R, Mild | 7 | 0 | 0 | 0 | 0 | 0 |
| Chills-non-SAE, R, Moderate | 6 | 0 | 0 | 0 | 0 | 0 |
| C.O.P.D.-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| C.O.P.D.-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0 | 0 | 1 | 2 | 1 | 4 |
| Chronic Sinusitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Confusional State-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Conjunctival Hyperaemia-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Conjunctivitis Allergic-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Conjunctivitis Bacterial-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Conjunctivitis Infective-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Conjunctivitis Infective-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Constipation-non-SAE, NR, Mild | 1 | 2 | 0 | 0 | 1 | 3 |
| Constipation-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Contusion-non-SAE, NR, Mild | 0 | 1 | 0 | 1 | 0 | 2 |
| Contusion-non-SAE, R, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Convulsion-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Convulsion-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Costochondritis-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Costochondritis-non-SAE, NR, Severe | 0 | 1 | 0 | 0 | 0 | 1 |
| Cough-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 2 | 2 |
| Cough-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Croup Infectious-non-SAE, NR, Mild | 0 | 2 | 0 | 1 | 0 | 3 |
| Croup Infectious-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 2 | 2 |
| Cryptosporidiosis Infection-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Cystitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Dental Caries-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Dermatitis-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Dermatitis-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Dermatitis Contact-non-SAE, NR, Moderate | 1 | 1 | 1 | 1 | 0 | 3 |
| Device Failure-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Diarrhoea-non-SAE, NR, Mild | 1 | 2 | 0 | 2 | 2 | 6 |
| Diarrhoea-non-SAE, NR, Moderate | 2 | 2 | 1 | 1 | 0 | 4 |
| Diarrhoea-non-SAE, R, Mild | 0 | 0 | 2 | 0 | 1 | 3 |
| Diarrhoea Haemorrhagic-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Diarrhoea Infectious-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Diverticulitis-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Drug Eruption-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Dyspepsia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Dyspnoea-non-SAE, NR, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Dyspnoea-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Dyspnoea-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Ear Infection-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 1 | 1 |
| Ear Pain-non-SAE, NR, Mild | 1 | 1 | 1 | 0 | 2 | 4 |
| Ear Pain-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Eczema-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 3 | 4 |
| Eczema-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Epistaxis-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Epistaxis-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 1 | 2 |
| Excoriation-non-SAE, NR, Mild | 0 | 0 | 0 | 2 | 0 | 2 |
| Exostosis-non-SAE, NR,Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Eye Infection Viral-non-SAE, NR, Moderate | 3 | 1 | 0 | 2 | 1 | 4 |
| Eye Irritation-non-SAE, R, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Eye Oedema-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Fall-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Fatigue-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Fatigue-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Fatigue-non-SAE, R, Mild | 1 | 4 | 0 | 2 | 0 | 6 |
| Fatigue-non-SAE, R, Moderate | 0 | 0 | 0 | 0 | 2 | 2 |
| Flank Pain-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Flatulence-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Flatulence-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Folliculitis-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Fungal Infection-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Furuncle-non-SAE, NR, Moderate | 0 | 1 | 1 | 0 | 0 | 2 |
| Gastric Ulcer-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Gastric Ulcer-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Gastroenteritis-non-SAE, NR, Mild | 1 | 0 | 0 | 1 | 0 | 1 |
| Gastroenteritis-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Gastroenteritis-non-SAE, R, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 2 | 2 | 0 | 0 | 0 | 2 |
| Gastroenteritis Viral-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 3 | 4 |
| Goitre-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Gravitational Oedema-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Haematochezia-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Haemoglobin Decreased-non-SAE, R, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Haemorrhoids-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Head Injury-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Headache-non-SAE, NR, Mild | 8 | 5 | 3 | 4 | 8 | 20 |
| Headache-non-SAE, NR, Moderate | 4 | 0 | 2 | 1 | 1 | 4 |
| Headache-non-SAE, NR, Severe | 0 | 0 | 1 | 0 | 1 | 2 |
| Headache-non-SAE, R, Mild | 19 | 6 | 1 | 2 | 8 | 17 |
| Headache-non-SAE, R, Moderate | 8 | 1 | 1 | 0 | 0 | 2 |
| Headache-non-SAE, R, Severe | 3 | 1 | 0 | 0 | 0 | 1 |
| Heart Rate Decreased-non-SAE, R, Mild | 0 | 0 | 3 | 0 | 0 | 3 |
| Heart Rate Increased-non-SAE, NR, Mild | 0 | 3 | 0 | 1 | 0 | 4 |
| Heart Rate Increased-non-SAE, R, Mild | 4 | 4 | 3 | 1 | 1 | 9 |
| Heart Rate Increased-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Hiatus Hernia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Hordeolum-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Hyperlipidaemia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Hypoxia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Implant Site Pain-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Infection-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 1 | 1 |
| Infection-non-SAE, NR, Moderate | 1 | 1 | 1 | 0 | 1 | 3 |
| Influenza-non-SAE, NR, Mild | 1 | 3 | 0 | 0 | 2 | 5 |
| Influenza-non-SAE, NR, Moderate | 2 | 4 | 0 | 1 | 2 | 7 |
| Infusion Related Reaction-non-SAE, R, Mild | 1 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Erythema-non-SAE, R, Mild | 0 | 3 | 0 | 0 | 0 | 3 |
| Infusion Site Haematoma-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 1 | 2 |
| Infusion Site Haematoma-non-SAE, R, Mild | 0 | 2 | 2 | 2 | 6 | 12 |
| Infusion Site Haematoma-non-SAE, R, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Infusion Site Haemorrhage-non-SAE, R, Mild | 0 | 2 | 0 | 0 | 0 | 2 |
| Infusion Site Irritation-non-SAE, R, Mild | 1 | 1 | 0 | 0 | 1 | 2 |
| Infusion Site Oedema-non-SAE, R, Mild | 0 | 3 | 0 | 0 | 0 | 3 |
| Infusion Site Pain-non-SAE, R, Mild | 1 | 9 | 2 | 2 | 1 | 14 |
| Infusion Site Pain-non-SAE, R, Moderate | 0 | 5 | 1 | 2 | 0 | 8 |
| Infusion Site Pruritus-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Pruritus-non-SAE, R, Mild | 0 | 2 | 1 | 1 | 0 | 4 |
| Infusion Site Pruritus-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Rash-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Rash-non-SAE, R, Mild | 0 | 1 | 1 | 0 | 1 | 3 |
| Infusion Site Reaction-non-SAE, R, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Infusion Site Swelling-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Swelling-non-SAE, R, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Infusion Site Vesicles-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Inguinal Mass-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Injection Site Haematoma-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Injection Site Haematoma-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Injection Site Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Insomnia-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 2 | 3 |
| Insomnia-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Intermit. Explosive Disorder-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Irritability-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Irritable Bowel Syndrome-non-SAE, NR, Moderate | 0 | 1 | 0 | 1 | 1 | 3 |
| Joint Dislocation-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Joint Sprain-non-SAE, NR, Mild | 0 | 2 | 0 | 0 | 0 | 2 |
| Joint Swelling-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Joint Swelling-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Laryngitis-non-SAE, NR, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Laryngitis-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Laryngitis Viral-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Lethargy-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Limb Injury-non-SAE, NR, Mild | 1 | 0 | 0 | 1 | 0 | 1 |
| Lip Ulceration-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Livedo Reticularis-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Lung Infection-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Lung Infection-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphadenopathy-non-SAE, NR, Mild | 2 | 0 | 1 | 0 | 2 | 3 |
| Malaise-non-SAE, NR, Moderate | 1 | 0 | 0 | 1 | 0 | 1 |
| Malaise-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Memory Impairment-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Middle Ear Effusion-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Migraine-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 1 | 2 |
| Migraine-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Migraine-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Migraine-non-SAE, R, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Migraine-non-SAE, R, Severe | 0 | 0 | 0 | 0 | 1 | 1 |
| Mouth Ulceration-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Muscle Strain-non-SAE, NR, Mild | 0 | 0 | 1 | 0 | 1 | 2 |
| Muscular Weakness-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Musculoskeletal Chest Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Musculoskeletal Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Musculoskeletal Pain-non-SAE, NR, Moderate | 0 | 0 | 1 | 1 | 1 | 3 |
| Myalgia-non-SAE, NR, Mild | 0 | 1 | 1 | 1 | 5 | 8 |
| Myalgia-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Myopia-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Nasal Congestion-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Nasal Congestion-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 1 | 2 |
| Nasal Disorder-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Nasal Mucosal Disorder-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Nasal Polyps-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Nasopharyngitis-non-SAE, NR, Mild | 5 | 1 | 0 | 1 | 4 | 6 |
| Nasopharyngitis-non-SAE, NR, Moderate | 0 | 1 | 0 | 1 | 4 | 6 |
| Nausea-non-SAE, NR, Mild | 1 | 3 | 1 | 2 | 5 | 11 |
| Nausea-non-SAE, NR, Moderate | 0 | 1 | 0 | 2 | 1 | 4 |
| Nausea-non-SAE, NR, Severe | 0 | 0 | 0 | 0 | 1 | 1 |
| Nausea-non-SAE, R, Mild | 4 | 1 | 1 | 3 | 1 | 6 |
| Nausea-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Oedema Peripheral-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Oedema Peripheral-non-SAE, R, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Oral Herpes-non-SAE, NR, Mild | 0 | 3 | 0 | 0 | 1 | 4 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 1 | 2 | 0 | 0 | 3 | 5 |
| Oropharyngeal Pain-non-SAE, NR, Moderate | 2 | 0 | 0 | 1 | 2 | 3 |
| Osteomyelitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Osteopenia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Otitis Externa-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Otitis Media-non-SAE, NR, Mild | 0 | 3 | 1 | 0 | 0 | 4 |
| Otitis Media-non-SAE, NR, Moderate | 0 | 2 | 0 | 3 | 2 | 7 |
| Pain-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Pain In Extremity-non-SAE, NR, Mild | 3 | 0 | 0 | 0 | 0 | 0 |
| Pain In Extremity-non-SAE, NR, Moderate | 0 | 0 | 1 | 1 | 0 | 2 |
| Pain In Extremity-non-SAE, R, Moderate | 1 | 0 | 0 | 1 | 0 | 1 |
| Pain In Extremity-non-SAE, R, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Paraesthesia-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Paronychia-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Periorbital Oedema-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Pharyngitis-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 1 | 2 |
| Pharyngitis-non-SAE, NR, Moderate | 2 | 1 | 0 | 2 | 0 | 3 |
| Pharyngitis Streptococcal-non-SAE, NR, Moderate | 0 | 2 | 0 | 0 | 0 | 2 |
| Pneumonia-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Pneumonia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 2 | 3 |
| Pneumonia Bacterial-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Pneumonia Streptococcal-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Procedural Pain-non-SAE, NR, Moderate | 1 | 0 | 0 | 1 | 2 | 3 |
| Pyrexia-non-SAE, NR, Mild | 1 | 3 | 0 | 0 | 10 | 13 |
| Pyrexia-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 2 | 2 |
| Pyrexia-non-SAE, R, Mild | 5 | 2 | 0 | 0 | 4 | 6 |
| Pyrexia-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 1 | 1 |
| Rales-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Rash-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Rash-non-SAE, R, Mild | 0 | 1 | 0 | 1 | 0 | 2 |
| Rash Erythematous-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 1 | 2 |
| Rash Macular-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Rash Papular-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Rash Pruritic-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Respiratory Rate Increased-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Respir. Tract Infect. Viral-non-SAE, NR, Mild | 2 | 2 | 0 | 0 | 1 | 3 |
| Respir. Tract Infect Viral-non-SAE, NR, Moderate | 1 | 1 | 0 | 0 | 0 | 1 |
| Rhinitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Rhinitis Allergic-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Rhinorrhoea-non-SAE, NR, Mild | 0 | 1 | 0 | 1 | 0 | 2 |
| Road Traffic Accident-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Scleritis-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Scleritis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Scoliosis-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Sinus Congestion-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 1 | 1 |
| Sinus Congestion-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Sinus Disorder-non-SAE, NR, Severe | 0 | 1 | 0 | 0 | 0 | 1 |
| Sinus Headache-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 1 | 1 |
| Sinus Headache-non-SAE, NR, Moderate | 2 | 1 | 0 | 1 | 0 | 2 |
| Sinusitis-non-SAE, NR, Mild | 3 | 0 | 0 | 1 | 4 | 5 |
| Sinusitis-non-SAE, NR, Moderate | 7 | 4 | 6 | 5 | 3 | 18 |
| Sinusitis-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Sinusitis Fungal-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Skin Laceration-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Skin Lesion-non-SAE, NR, Mild | 1 | 0 | 0 | 1 | 0 | 1 |
| Skin Papilloma-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Skin Warm-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Sports Injury-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Streptococcal Infection-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Subcutaneous Abscess-non-SAE, NR, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Suicidal Ideation-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Sunburn-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Tendonitis-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Tooth Fracture-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Tooth Infection-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Toothache-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 1 | 2 |
| Tourette's Disorder-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Upper Respir. Tract Congestion-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Upper Respir. Tract Infection-non-SAE, NR, Mild | 4 | 3 | 3 | 6 | 8 | 20 |
| Upper Respir. Tract Infect.-non-SAE, NR, Moderate | 2 | 1 | 0 | 1 | 3 | 5 |
| Urinary Tract Infection-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 1 | 1 |
| Urticaria-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Urticaria-non-SAE, R, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Vaginal Lesion-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Vaginitis Bacterial-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Varicose Vein-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Varicose Vein-non-SAE, NR, Severe | 0 | 0 | 0 | 0 | 1 | 1 |
| Vestibulitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Viral Infection-non-SAE, NR, Mild | 2 | 2 | 0 | 0 | 0 | 2 |
| Viral Infection-non-SAE, NR, Moderate | 3 | 0 | 0 | 1 | 0 | 1 |
| Viral Skin Infection-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Viral Upper Respir. Tract Infect-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Viral Up. Respir Tract Infec-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Vitamin D Deficiency-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Vomiting-non-SAE, NR, Mild | 2 | 1 | 1 | 1 | 4 | 7 |
| Vomiting-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Vomiting-non-SAE, R, Mild | 8 | 0 | 0 | 1 | 1 | 2 |
| Vomiting-non-SAE, R, Moderate | 1 | 0 | 0 | 2 | 0 | 2 |
| Vulvovaginal Candidiasis-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Vulvovaginal Mycotic Infection-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Vulvovaginal Mycotic Infect.-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Wheezing-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Wound-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.
| AEs per infusion | Study Part 1, IV Administration | Study Part 2, SC Administration | Study Part 3a, SC Administration | Study Part 3b, SC Administration | Study Extension, SC Administration | Total SC (Parts 2, 3a, 3b, Extension) |
|---|---|---|---|---|---|---|
| Abdominal Discomfort- non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Abdominal Distension-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.29 |
| Abdominal Distension-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.17 | 0.08 | 0.13 |
| Abdominal Distension-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Abdominal Distension-non-SAE, R, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Abdominal Pain-non-SAE, NR, Mild | 0.25 | 0.00 | 0.17 | 0.00 | 0.05 | 0.11 |
| Abdominal Pain-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Abdominal Pain Upper-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 |
| Abdominal Pain Upper-non-SAE, R, Mild | 0.00 | 0.10 | 0.17 | 0.00 | 0.00 | 0.13 |
| Abdominal Tenderness-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Acne-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Acne-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Acute Sinusitis-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Addison's Disease-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Addison's Disease-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Alopecia-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ammonia Increased-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Animal Bite-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Anorexia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Anxiety-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Aphthous Stomatitis-non-SAE, NR, Mild | 0.00 | 0.08 | 0.17 | 0.00 | 0.14 | 0.14 |
| Arthralgia-non-SAE, NR, Moderate | 0.00 | 0.10 | 0.17 | 0.17 | 0.04 | 0.11 |
| Arthralgia-non-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Arthralgia-non-SAE, R, Mild | 0.25 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Arthralgia-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Arthritis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Arthropod Bite-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.03 | 0.06 |
| Asthenia-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Asthenia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Asthma-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Asthma-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.17 | 0.08 | 0.03 | 0.04 |
| Asthma-non-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Asthma-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Asthma Exercise Induced-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| ADHD-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Back Pain-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.09 | 0.00 | 0.09 |
| Back Pain-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.17 | 0.00 | 0.17 |
| Back Pain-non-SAE, R, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Biliary Tract Infection Bacterial-SAE, NR, Moderat | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Blepharitis-non-SAE,NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Blepharitis-non-SAE,NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| B.P. Diastolic Decreased-non-SAE, R, Mild | 0.00 | 0.00 | 0.33 | 0.00 | 0.00 | 0.33 |
| Blood Pressure Increased-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.17 |
| Blood Pressure Increased-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| B.P. Systolic Increased-non-SAE, NR, Mild | 0.00 | 0.08 | 0.17 | 0.00 | 0.00 | 0.12 |
| B.P. Systolic Increased-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| B.P. Systolic Increased-non-SAE, R, Mild | 0.25 | 0.16 | 0.17 | 0.00 | 0.00 | 0.17 |
| B.P. Systolic Increased-non-SAE, R, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Breast Tenderness-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Breath Sounds Abnormal-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Bronchitis-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.17 | 0.06 | 0.08 |
| Bronchitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.17 | 0.00 | 0.07 | 0.08 |
| Bursitis-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Candidiasis-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cardiac Murmur-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Centrl Venous Catheterisation-non-SAE, NR, Moderat | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Cervical Spinal Stenosis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Chest Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Chest Pain-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Chills-non-SAE, R, Mild | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Chills-non-SAE, R, Moderate | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| C.O.P.D.-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| C.O.P.D.-non-SAE, NR, Severe | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.08 | 0.03 | 0.08 |
| Chronic Sinusitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Confusional State-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Conjunctival Hyperaemia-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Conjunctivitis Allergic-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Conjunctivitis Bacterial-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Conjunctivitis Infective-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Conjunctivitis Infective-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Constipation-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.03 | 0.07 |
| Constipation-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Contusion-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Contusion-non-SAE, R, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Convulsion-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Convulsion-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Costochondritis-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Costochondritis-non-SAE, NR, Severe | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Cough-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Cough-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Croup Infectious-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Croup Infectious-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.11 |
| Cryptosporidiosis Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Cystitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Dental Caries-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Dermatitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Dermatitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dermatitis Contact-non-SAE, NR, Moderate | 0.25 | 0.08 | 0.17 | 0.08 | 0.00 | 0.08 |
| Device Failure-non-SAE, NR, Mild | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Diarrhoea-non-SAE, NR, Mild | 0.25 | 0.07 | 0.00 | 0.17 | 0.05 | 0.06 |
| Diarrhoea-non-SAE, NR, Moderate | 0.25 | 0.17 | 0.17 | 0.08 | 0.00 | 0.17 |
| Diarrhoea-non-SAE, R, Mild | 0.00 | 0.00 | 0.33 | 0.00 | 0.05 | 0.19 |
| Diarrhoea Haemorrhagic-non-SAE, NR,Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Diarrhoea Infectious-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Diverticulitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Drug Eruption-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dyspepsia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Dyspnoea-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Dyspnoea-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Dyspnoea-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ear Infection-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Ear Pain-non-SAE, NR, Mild | 0.25 | 0.06 | 0.17 | 0.00 | 0.04 | 0.05 |
| Ear Pain-non-SAE, R, Moderate | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.06 |
| Eczema-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.04 | 0.06 |
| Eczema-non-SAE, NR, Severe | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Epistaxis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Epistaxis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.14 | 0.00 | 0.07 | 0.10 |
| Excoriation-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.17 |
| Exostosis-non-SAE, NR,Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Eye Infection Viral-non-SAE, NR, Moderate | 0.38 | 0.10 | 0.00 | 0.08 | 0.04 | 0.08 |
| Eye Irritation-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Eye Oedema-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Fall-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Fatigue-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.11 |
| Fatigue-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Fatigue-non-SAE, R, Mild | 0.25 | 0.16 | 0.00 | 0.17 | 0.00 | 0.21 |
| Fatigue-non-SAE, R, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Flank Pain-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Flatulence-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Flatulence-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Folliculitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fungal Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Furuncle-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.17 | 0.00 | 0.00 | 0.12 |
| Gastric Ulcer-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.09 |
| Gastric Ulcer-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Gastroenteritis-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Gastroenteritis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Gastroenteritis-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 0.23 | 0.06 | 0.00 | 0.00 | 0.00 | 0.06 |
| Gastroenteritis Viral-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.05 | 0.07 |
| Goitre-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gravitational Oedema-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Haematochezia-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Haemoglobin Decreased-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Haemorrhoids-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Head Injury-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Headache-non-SAE, NR, Mild | 0.23 | 0.17 | 0.17 | 0.08 | 0.04 | 0.08 |
| Headache-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.17 | 0.08 | 0.03 | 0.13 |
| Headache-non-SAE, NR, Severe | 0.00 | 0.00 | 0.17 | 0.00 | 0.07 | 0.12 |
| Headache-non-SAE, R, Mild | 1.10 | 0.20 | 0.17 | 0.17 | 0.11 | 0.14 |
| Headache-non-SAE, R, Moderate | 0.63 | 0.07 | 0.17 | 0.00 | 0.00 | 0.24 |
| Headache-non-SAE, R, Severe | 0.38 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Heart Rate Decreased-non-SAE, R, Mild | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.50 |
| Heart Rate Increased-non-SAE, NR, Mild | 0.00 | 0.25 | 0.00 | 0.08 | 0.00 | 0.17 |
| Heart Rate Increased-non-SAE, R, Mild | 0.25 | 0.08 | 0.25 | 0.08 | 0.03 | 0.08 |
| Heart Rate Increased-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hiatus Hernia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Hordeolum-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Hyperlipidaemia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Hypoxia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Implant Site Pain-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Infection-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Infection-non-SAE, NR, Moderate | 0.20 | 0.08 | 0.17 | 0.00 | 0.04 | 0.08 |
| Influenza-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.03 | 0.08 |
| Influenza-non-SAE, NR, Moderate | 0.23 | 0.07 | 0.00 | 0.08 | 0.04 | 0.07 |
| Infusion Related Reaction-non-SAE, R, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Erythema-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Haematoma-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.03 | 0.06 |
| Infusion Site Haematoma-non-SAE, R, Mild | 0.00 | 0.07 | 0.17 | 0.17 | 0.04 | 0.07 |
| Infusion Site Haematoma-non-SAE, R, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Infusion Site Haemorrhage-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Irritation-non-SAE, R, Mild | 0.25 | 0.10 | 0.00 | 0.00 | 0.05 | 0.07 |
| Infusion Site Oedema-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Pain-non-SAE, R, Mild | 0.20 | 0.14 | 0.15 | 0.08 | 0.04 | 0.16 |
| Infusion Site Pain-non-SAE, R, Moderate | 0.00 | 0.07 | 0.17 | 0.16 | 0.00 | 0.16 |
| Infusion Site Pruritus-non-SAE, NR, Moderate | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Infusion Site Pruritus-non-SAE, R, Mild | 0.00 | 0.15 | 0.17 | 0.08 | 0.00 | 0.16 |
| Infusion Site Pruritus-non-SAE, R, Moderate | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Infusion Site Rash-non-SAE, NR, Mild | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.06 |
| Infusion Site Rash-non-SAE, R, Mild | 0.00 | 0.08 | 0.17 | 0.00 | 0.03 | 0.08 |
| Infusion Site Reaction-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.09 |
| Infusion Site Swelling-non-SAE, R, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Infusion Site Swelling-non-SAE, R, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Vesicles-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Inguinal Mass-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Injection Site Haematoma-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Injection Site Haematoma-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Injection Site Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Insomnia-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.03 | 0.03 |
| Insomnia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Intermit. Explosive Disorder-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Irritability-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.13 |
| Irritable Bowel Syndrome-non-SAE, NR, Moderate | 0.00 | 0.06 | 0.00 | 0.08 | 0.04 | 0.06 |
| Joint Dislocation-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Joint Sprain-non-SAE, NR, Mild | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.17 |
| Joint Swelling-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Joint Swelling-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Laryngitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Laryngitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Laryngitis Viral-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Lethargy-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Limb Injury-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Lip Ulceration-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Livedo Reticularis-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Lung Infection-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Lung Infection-non-SAE, NR, Severe | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Lymphadenopathy-non-SAE, NR, Mild | 0.25 | 0.00 | 0.17 | 0.00 | 0.04 | 0.05 |
| Malaise-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Malaise-non-SAE, R, Moderate | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.10 |
| Memory Impairment-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Middle Ear Effusion-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Migraine-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.03 | 0.06 |
| Migraine-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Migraine-non-SAE, NR, Severe | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Migraine-non-SAE, R, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Migraine-non-SAE, R, Severe | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Mouth Ulceration-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Muscle Strain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.03 | 0.10 |
| Muscular Weakness-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Musculoskeletal Chest Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.09 |
| Musculoskeletal Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Musculoskeletal Pain-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.07 | 0.04 | 0.07 |
| Myalgia-non-SAE, NR, Mild | 0.00 | 0.08 | 0.17 | 0.08 | 0.09 | 0.09 |
| Myalgia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Myopia-non-SAE, NR, Mild | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.10 |
| Nasal Congestion-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.06 |
| Nasal Congestion-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.04 | 0.10 |
| Nasal Disorder-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Nasal Mucosal Disorder-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Nasal Polyps-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Nasopharyngitis-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.08 | 0.04 | 0.04 |
| Nasopharyngitis-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.07 | 0.07 | 0.07 |
| Nausea-non-SAE, NR, Mild | 0.25 | 0.08 | 0.17 | 0.08 | 0.12 | 0.08 |
| Nausea-non-SAE, NR, Moderate | 0.00 | 0.07 | 0.00 | 0.17 | 0.03 | 0.07 |
| Nausea-non-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Nausea-non-SAE, R, Mild | 0.75 | 0.08 | 0.17 | 0.27 | 0.04 | 0.13 |
| Nausea-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Oedema Peripheral-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Oedema Peripheral-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Oral Herpes-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.03 | 0.07 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 0.20 | 0.08 | 0.00 | 0.00 | 0.07 | 0.07 |
| Oropharyngeal Pain-non-SAE, NR, Moderate | 0.23 | 0.00 | 0.00 | 0.08 | 0.05 | 0.07 |
| Osteomyelitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Osteopenia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Otitis Externa-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Otitis Media-non-SAE, NR, Mild | 0.00 | 0.13 | 0.17 | 0.00 | 0.00 | 0.17 |
| Otitis Media-non-SAE, NR, Moderate | 0.00 | 0.17 | 0.00 | 0.13 | 0.11 | 0.14 |
| Pain-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pain In Extremity-non-SAE, NR, Mild | 0.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pain In Extremity-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.08 | 0.00 | 0.13 |
| Pain In Extremity-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Pain In Extremity-non-SAE, R, Severe | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Paraesthesia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Paronychia-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Periorbital Oedema-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Pharyngitis-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.05 | 0.07 |
| Pharyngitis-non-SAE, NR, Moderate | 0.50 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Pharyngitis Streptococcal-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Pneumonia-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Pneumonia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.04 | 0.06 |
| Pneumonia Bacterial-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Pneumonia Streptococcal-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Procedural Pain-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.08 | 0.04 | 0.04 |
| Pyrexia-non-SAE, NR, Mild | 0.25 | 0.07 | 0.00 | 0.00 | 0.07 | 0.07 |
| Pyrexia-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Pyrexia-non-SAE, R, Mild | 0.63 | 0.17 | 0.00 | 0.00 | 0.07 | 0.07 |
| Pyrexia-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Rales-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Rash-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Rash-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Rash Erythematous-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.05 | 0.07 |
| Rash Macular-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Rash Papular-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Rash Pruritic-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Respiratory Rate Increased-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Respir. Tract Infect. Viral-non-SAE, NR, Mild | 0.25 | 0.17 | 0.00 | 0.00 | 0.03 | 0.10 |
| Respir. Tract Infect Viral-non-SAE, NR, Moderate | 0.25 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Rhinitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.09 |
| Rhinitis Allergic-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Rhinorrhoea-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Road Traffic Accident-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Scleritis-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Scleritis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Scoliosis-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Sinus Congestion-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Sinus Congestion-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Sinus Disorder-non-SAE, NR, Severe | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.06 |
| Sinus Headache-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Sinus Headache-non-SAE, NR, Moderate | 0.50 | 0.07 | 0.00 | 0.08 | 0.00 | 0.08 |
| Sinusitis-non-SAE, NR, Mild | 0.46 | 0.00 | 0.00 | 0.08 | 0.04 | 0.04 |
| Sinusitis-non-SAE, NR, Moderate | 0.25 | 0.07 | 0.17 | 0.08 | 0.04 | 0.08 |
| Sinusitis-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sinusitis Fungal-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Skin Laceration-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Skin Lesion-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Skin Papilloma-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Skin Warm-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sports Injury-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Streptococcal Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Subcutaneous Abscess-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Suicidal Ideation-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sunburn-non-SAE, NR, Severe | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tendonitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tooth Fracture-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Tooth Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Toothache-non-SAE, NR, Moderate | 0.00 | 0.07 | 0.00 | 0.00 | 0.03 | 0.05 |
| Tourette's Disorder-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Upper Respir. Tract Congestion-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Upper Respir. Tract Infection-non-SAE, NR, Mild | 0.25 | 0.08 | 0.17 | 0.08 | 0.05 | 0.08 |
| Upper Respir. Tract Infect.-non-SAE, NR, Moderate | 0.25 | 0.08 | 0.00 | 0.08 | 0.05 | 0.07 |
| Urinary Tract Infection-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Urticaria-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Urticaria-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Vaginal Lesion-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Vaginitis Bacterial-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Varicose Vein-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Varicose Vein-non-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Vestibulitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Viral Infection-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Viral Infection-non-SAE, NR, Moderate | 0.38 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Viral Skin Infection-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Viral Upper Respir. Tract Infect-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Viral Up. Respir Tract Infec-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Vitamin D Deficiency-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Vomiting-non-SAE, NR, Mild | 0.25 | 0.07 | 0.17 | 0.08 | 0.04 | 0.07 |
| Vomiting-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Vomiting-non-SAE, R, Mild | 0.75 | 0.00 | 0.00 | 0.09 | 0.05 | 0.07 |
| Vomiting-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.18 | 0.00 | 0.18 |
| Vulvovaginal Candidiasis-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Vulvovaginal Mycotic Infection-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Vulvovaginal Mycotic Infect.-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Wheezing-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.09 |
| Wound-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR
| Adverse events | Study Part 1, IV Administration | Study Part 2, SC Administration | Study Part 3a, SC Administration | Study Part 3b, SC Administration | Study Extension, SC Administration | Total SC (Study Parts 2, 3a, 3b, Extension) |
|---|---|---|---|---|---|---|
| Abdominal Discomfort- non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Abdominal Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Abdominal Pain-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 2 | 2 |
| Abdominal Pain Upper-non-SAE, R, Mild | 0 | 3 | 0 | 0 | 0 | 3 |
| Acne-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Acute Sinusitis-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Alopecia-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Ammonia Increased-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Animal Bite-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Anorexia-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Anxiety-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Aphthous Stomatitis-non-SAE, NR, Mild | 0 | 1 | 1 | 0 | 2 | 4 |
| Arthralgia-non-SAE, NR, Moderate | 0 | 2 | 0 | 0 | 0 | 2 |
| Arthralgia-non-SAE, R, Mild | 1 | 0 | 1 | 0 | 0 | 1 |
| Arthralgia-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Arthritis-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Arthropod Bite-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 1 | 2 |
| Asthenia-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Asthma-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Asthma-non-SAE, NR, Moderate | 3 | 0 | 1 | 1 | 3 | 5 |
| Asthma-non-SAE, NR, Severe | 0 | 0 | 0 | 1 | 0 | 1 |
| Asthma-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Asthma Exercise Induced-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| ADHD-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Back Pain-non-SAE, NR, Mild | 1 | 0 | 0 | 1 | 0 | 1 |
| Back Pain-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Back Pain-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Biliary Tract Infection Bacterial-SAE, NR, Moderat | 0 | 1 | 0 | 0 | 0 | 1 |
| Blepharitis-non-SAE,NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| B.P. Diastolic Decreased-non-SAE, R, Mild | 0 | 0 | 2 | 0 | 0 | 2 |
| Blood Pressure Increased-non-SAE, NR, Mild | 0 | 0 | 0 | 2 | 0 | 2 |
| Blood Pressure Increased-non-SAE, R, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| B.P. Systolic Increased-non-SAE, NR, Mild | 0 | 1 | 1 | 0 | 0 | 2 |
| B.P. Systolic Increased-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| B.P. Systolic Increased-non-SAE, R, Mild | 1 | 4 | 2 | 0 | 0 | 6 |
| B.P. Systolic Increased-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Breast Tenderness-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Bronchitis-non-SAE, NR, Mild | 1 | 1 | 0 | 2 | 2 | 5 |
| Bronchitis-non-SAE, NR, Moderate | 1 | 0 | 1 | 0 | 2 | 3 |
| Bursitis-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Candidiasis-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Cardiac Murmur-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Centrl Venous Catheterisation-non-SAE, NR, Moderat | 0 | 0 | 0 | 0 | 1 | 1 |
| Cervical Spinal Stenosis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Chest Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Chest Pain-SAE, NR, Severe | 0 | 0 | 0 | 1 | 0 | 1 |
| Chills-non-SAE, R, Mild | 7 | 0 | 0 | 0 | 0 | 0 |
| Chills-non-SAE, R, Moderate | 6 | 0 | 0 | 0 | 0 | 0 |
| C.O.P.D.-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| C.O.P.D.-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0 | 0 | 1 | 1 | 1 | 3 |
| Confusional State-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Conjunctival Hyperaemia-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Conjunctivitis Allergic-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Conjunctivitis Infective-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Constipation-non-SAE, NR, Mild | 1 | 2 | 0 | 0 | 1 | 3 |
| Constipation-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Contusion-non-SAE, NR, Mild | 0 | 1 | 0 | 1 | 0 | 2 |
| Contusion-non-SAE, R, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Convulsion-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Convulsion-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Cough-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Cough-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Croup Infectious-non-SAE, NR, Mild | 0 | 2 | 0 | 1 | 0 | 3 |
| Croup Infectious-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 2 | 2 |
| Cryptosporidiosis Infection-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Dental Caries-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Dermatitis-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Dermatitis Contact-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Device Failure-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Diarrhoea-non-SAE, NR, Mild | 1 | 1 | 0 | 0 | 1 | 2 |
| Diarrhoea-non-SAE, NR, Moderate | 1 | 2 | 1 | 0 | 0 | 3 |
| Diarrhoea-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 1 | 1 |
| Diarrhoea Haemorrhagic-non-SAE, NR,Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Diarrhoea Infectious-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Diverticulitis-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Drug Eruption-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Dyspnoea-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Dyspnoea-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Ear Infection-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 1 | 1 |
| Ear Pain-non-SAE, NR, Mild | 0 | 1 | 1 | 0 | 1 | 3 |
| Ear Pain-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Eczema-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 3 | 4 |
| Eczema-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Epistaxis-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Epistaxis-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 1 | 2 |
| Excoriation-non-SAE, NR, Mild | 0 | 0 | 0 | 2 | 0 | 2 |
| Eye Infection Viral-non-SAE, NR, Moderate | 3 | 1 | 0 | 1 | 1 | 3 |
| Fall-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Fatigue-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Fatigue-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Fatigue-non-SAE, R, Mild | 1 | 3 | 0 | 2 | 0 | 5 |
| Fatigue-non-SAE, R, Moderate | 0 | 0 | 0 | 0 | 2 | 2 |
| Flank Pain-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Fungal Infection-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Furuncle-non-SAE, NR, Moderate | 0 | 1 | 1 | 0 | 0 | 2 |
| Gastric Ulcer-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Gastric Ulcer-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Gastroenteritis-non-SAE, NR, Mild | 1 | 0 | 0 | 1 | 0 | 1 |
| Gastroenteritis-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Gastroenteritis-non-SAE, R, Mild | 0 | 2 | 0 | 0 | 0 | 0 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 1 | 2 | 0 | 0 | 0 | 2 |
| Gastroenteritis Viral-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 3 | 4 |
| Goitre-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Gravitational Oedema-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Haematochezia-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Haemoglobin Decreased-non-SAE, R, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Haemorrhoids-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Head Injury-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Headache-non-SAE, NR, Mild | 7 | 3 | 2 | 3 | 8 | 16 |
| Headache-non-SAE, NR, Moderate | 4 | 0 | 2 | 1 | 1 | 4 |
| Headache-non-SAE, NR, Severe | 0 | 0 | 1 | 0 | 1 | 2 |
| Headache-non-SAE, R, Mild | 19 | 4 | 1 | 2 | 8 | 15 |
| Headache-non-SAE, R, Moderate | 8 | 1 | 1 | 0 | 0 | 2 |
| Headache-non-SAE, R, Severe | 3 | 1 | 0 | 0 | 0 | 1 |
| Heart Rate Decreased-non-SAE, R, Mild | 0 | 0 | 3 | 0 | 0 | 3 |
| Heart Rate Increased-non-SAE, NR, Mild | 0 | 3 | 0 | 1 | 0 | 4 |
| Heart Rate Increased-non-SAE, R, Mild | 4 | 4 | 3 | 1 | 1 | 9 |
| Heart Rate Increased-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Hiatus Hernia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Hordeolum-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Hyperlipidaemia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Hypoxia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Implant Site Pain-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Infection-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 1 | 1 |
| Infection-non-SAE, NR, Moderate | 1 | 1 | 0 | 0 | 0 | 1 |
| Influenza-non-SAE, NR, Mild | 1 | 3 | 0 | 0 | 2 | 5 |
| Influenza-non-SAE, NR, Moderate | 1 | 4 | 0 | 0 | 2 | 6 |
| Infusion Related Reaction-non-SAE, R, Mild | 1 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Erythema-non-SAE, R, Mild | 0 | 3 | 0 | 0 | 0 | 3 |
| Infusion Site Haematoma-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 1 | 2 |
| Infusion Site Haematoma-non-SAE, R, Mild | 0 | 2 | 2 | 2 | 5 | 11 |
| Infusion Site Haematoma-non-SAE, R, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Infusion Site Haemorrhage-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Irritation-non-SAE, R, Mild | 1 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Oedema-non-SAE, R, Mild | 0 | 2 | 0 | 0 | 0 | 2 |
| Infusion Site Pain-non-SAE, R, Mild | 1 | 8 | 2 | 2 | 1 | 13 |
| Infusion Site Pain-non-SAE, R, Moderate | 0 | 5 | 1 | 2 | 0 | 8 |
| Infusion Site Pruritus-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Pruritus-non-SAE, R, Mild | 0 | 1 | 1 | 1 | 0 | 3 |
| Infusion Site Pruritus-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Rash-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Rash-non-SAE, R, Mild | 0 | 1 | 1 | 0 | 1 | 3 |
| Infusion Site Reaction-non-SAE, R, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Infusion Site Swelling-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Swelling-non-SAE, R, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Infusion Site Vesicles-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Inguinal Mass-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Injection Site Haematoma-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Insomnia-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 2 | 3 |
| Insomnia-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Intermit. Explosive Disorder-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Irritability-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Irritable Bowel Syndrome-non-SAE, NR, Moderate | 0 | 1 | 0 | 1 | 1 | 3 |
| Joint Dislocation-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Laryngitis-non-SAE, NR, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Laryngitis-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Lethargy-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Limb Injury-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Lip Ulceration-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Livedo Reticularis-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Lung Infection-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Lung Infection-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphadenopathy-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 2 | 2 |
| Malaise-non-SAE, NR, Moderate | 1 | 0 | 0 | 1 | 0 | 1 |
| Malaise-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Middle Ear Effusion-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Migraine-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 1 | 2 |
| Migraine-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Migraine-non-SAE, R, Severe | 0 | 0 | 0 | 0 | 1 | 1 |
| Mouth Ulceration-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Muscular Weakness-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Musculoskeletal Chest Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Musculoskeletal Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Musculoskeletal Pain-non-SAE, NR, Moderate | 0 | 0 | 1 | 1 | 1 | 3 |
| Myalgia-non-SAE, NR, Mild | 0 | 1 | 1 | 1 | 5 | 8 |
| Myalgia-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Myopia-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Nasal Congestion-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Nasal Congestion-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Nasal Disorder-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Nasal Mucosal Disorder-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Nasal Polyps-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Nasopharyngitis-non-SAE, NR, Mild | 3 | 0 | 0 | 1 | 2 | 3 |
| Nasopharyngitis-non-SAE, NR, Moderate | 0 | 1 | 0 | 1 | 2 | 4 |
| Nausea-non-SAE, NR, Mild | 1 | 2 | 0 | 1 | 1 | 4 |
| Nausea-non-SAE, NR, Moderate | 0 | 1 | 0 | 2 | 1 | 4 |
| Nausea-non-SAE, NR, Severe | 0 | 0 | 0 | 0 | 1 | 1 |
| Nausea-non-SAE, R, Mild | 4 | 0 | 0 | 3 | 0 | 3 |
| Oedema Peripheral-non-SAE, R, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Oral Herpes-non-SAE, NR, Mild | 0 | 2 | 0 | 0 | 1 | 3 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 0 | 2 | 0 | 0 | 3 | 5 |
| Oropharyngeal Pain-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 1 | 2 |
| Osteomyelitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Otitis Externa-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Otitis Media-non-SAE, NR, Mild | 0 | 3 | 1 | 0 | 0 | 4 |
| Otitis Media-non-SAE, NR, Moderate | 0 | 2 | 0 | 3 | 2 | 7 |
| Pain-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Pain In Extremity-non-SAE, NR, Mild | 3 | 0 | 0 | 0 | 0 | 0 |
| Pain In Extremity-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Pain In Extremity-non-SAE, R, Moderate | 1 | 0 | 0 | 1 | 0 | 1 |
| Pain In Extremity-non-SAE, R, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Paraesthesia-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Paronychia-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Periorbital Oedema-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Pharyngitis-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Pharyngitis-non-SAE, NR, Moderate | 2 | 1 | 0 | 1 | 0 | 2 |
| Pharyngitis Streptococcal-non-SAE, NR, Moderate | 0 | 2 | 0 | 0 | 0 | 2 |
| Pneumonia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 2 | 3 |
| Pneumonia Streptococcal-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Procedural Pain-non-SAE, NR, Moderate | 1 | 0 | 0 | 1 | 2 | 3 |
| Pyrexia-non-SAE, NR, Mild | 1 | 2 | 0 | 0 | 9 | 11 |
| Pyrexia-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 2 | 2 |
| Pyrexia-non-SAE, R, Mild | 5 | 2 | 0 | 0 | 4 | 6 |
| Pyrexia-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 1 | 1 |
| Rash-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Rash-non-SAE, R, Mild | 0 | 1 | 0 | 1 | 0 | 2 |
| Rash Erythematous-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 1 | 2 |
| Rash Macular-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Rash Papular-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Rash Pruritic-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Respiratory Rate Increased-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Respir. Tract Infect. Viral-non-SAE, NR, Mild | 2 | 2 | 0 | 0 | 0 | 2 |
| Respir. Tract Infect Viral-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Rhinitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Rhinitis Allergic-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Rhinorrhoea-non-SAE, NR, Mild | 0 | 1 | 0 | 1 | 0 | 2 |
| Road Traffic Accident-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Scleritis-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Scleritis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Scoliosis-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Sinus Congestion-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 1 | 1 |
| Sinus Congestion-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Sinus Disorder-non-SAE, NR, Severe | 0 | 1 | 0 | 0 | 0 | 1 |
| Sinus Headache-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 1 | 1 |
| Sinus Headache-non-SAE, NR, Moderate | 2 | 1 | 0 | 1 | 0 | 2 |
| Sinusitis-non-SAE, NR, Mild | 3 | 0 | 0 | 1 | 3 | 4 |
| Sinusitis-non-SAE, NR, Moderate | 6 | 4 | 4 | 4 | 3 | 15 |
| Sinusitis-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Sinusitis Fungal-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Skin Laceration-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Skin Lesion-non-SAE, NR, Mild | 1 | 0 | 0 | 1 | 0 | 1 |
| Skin Papilloma-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Skin Warm-non-SAE, R, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Streptococcal Infection-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Subcutaneous Abscess-non-SAE, NR, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Suicidal Ideation-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Sunburn-non-SAE, NR, Severe | 1 | 0 | 0 | 0 | 0 | 0 |
| Tendonitis-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Tooth Fracture-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Tooth Infection-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Toothache-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 1 | 2 |
| Tourette's Disorder-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Upper Respir. Tract Congestion-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Upper Respir. Tract Infection-non-SAE, NR, Mild | 2 | 3 | 3 | 5 | 7 | 18 |
| Upper Respir. Tract Infect.-non-SAE, NR, Moderate | 1 | 1 | 0 | 1 | 3 | 5 |
| Urinary Tract Infection-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Urticaria-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 2 | 2 |
| Urticaria-non-SAE, R, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Vaginal Lesion-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Vaginitis Bacterial-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Varicose Vein-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Varicose Vein-non-SAE, NR, Severe | 0 | 0 | 0 | 0 | 1 | 1 |
| Viral Infection-non-SAE, NR, Mild | 2 | 2 | 0 | 0 | 0 | 2 |
| Viral Infection-non-SAE, NR, Moderate | 3 | 0 | 0 | 1 | 0 | 1 |
| Viral Skin Infection-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Viral Upper Respir. Tract Infect-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Vitamin D Deficiency-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Vomiting-non-SAE, NR, Mild | 1 | 1 | 1 | 1 | 4 | 7 |
| Vomiting-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Vomiting-non-SAE, R, Mild | 8 | 0 | 0 | 1 | 1 | 2 |
| Vomiting-non-SAE, R, Moderate | 1 | 0 | 0 | 2 | 0 | 2 |
| Vulvovaginal Candidiasis-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Vulvovaginal Mycotic Infection-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Wheezing-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.
| AEs per infusion | Study Part 1, IV Administration | Study Part 2, SC Administration | Study Part 3a, SC Administration | Study Part 3b, SC Administration | Study Extension, SC Administration | Total SC (Parts 2, 3a, 3b, Extension) |
|---|---|---|---|---|---|---|
| Abdominal Discomfort- non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Abdominal Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Abdominal Pain-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Abdominal Pain Upper-non-SAE, R, Mild | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.10 |
| Acne-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Acute Sinusitis-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Alopecia-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ammonia Increased-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Animal Bite-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Anorexia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Anxiety-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Aphthous Stomatitis-non-SAE, NR, Mild | 0.00 | 0.08 | 0.17 | 0.00 | 0.14 | 0.14 |
| Arthralgia-non-SAE, NR, Moderate | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 | 0.11 |
| Arthralgia-non-SAE, R, Mild | 0.25 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Arthralgia-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Arthritis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Arthropod Bite-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.03 | 0.06 |
| Asthenia-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Asthma-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Asthma-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.17 | 0.08 | 0.03 | 0.04 |
| Asthma-non-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Asthma-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Asthma Exercise Induced-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| ADHD-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Back Pain-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.09 | 0.00 | 0.09 |
| Back Pain-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Back Pain-non-SAE, R, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Biliary Tract Infection Bacterial-SAE, NR, Moderat | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Blepharitis-non-SAE,NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| B.P. Diastolic Decreased-non-SAE, R, Mild | 0.00 | 0.00 | 0.33 | 0.00 | 0.00 | 0.33 |
| Blood Pressure Increased-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.17 |
| Blood Pressure Increased-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| B.P. Systolic Increased-non-SAE, NR, Mild | 0.00 | 0.08 | 0.17 | 0.00 | 0.00 | 0.12 |
| B.P. Systolic Increased-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| B.P. Systolic Increased-non-SAE, R, Mild | 0.25 | 0.16 | 0.17 | 0.00 | 0.00 | 0.17 |
| B.P. Systolic Increased-non-SAE, R, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Breast Tenderness-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Bronchitis-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.17 | 0.06 | 0.08 |
| Bronchitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.17 | 0.00 | 0.08 | 0.12 |
| Bursitis-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Candidiasis-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cardiac Murmur-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Centrl Venous Catheterisation-non-SAE, NR, Moderat | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Cervical Spinal Stenosis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Chest Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Chest Pain-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Chills-non-SAE, R, Mild | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Chills-non-SAE, R, Moderate | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| C.O.P.D.-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| C.O.P.D.-non-SAE, NR, Severe | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.08 | 0.03 | 0.08 |
| Confusional State-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Conjunctival Hyperaemia-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Conjunctivitis Allergic-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Conjunctivitis Infective-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Constipation-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.03 | 0.07 |
| Constipation-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Contusion-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Contusion-non-SAE, R, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Convulsion-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Convulsion-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cough-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Cough-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Croup Infectious-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Croup Infectious-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.11 |
| Cryptosporidiosis Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Dental Caries-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Dermatitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Dermatitis Contact-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Device Failure-non-SAE, NR, Mild | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Diarrhoea-non-SAE, NR, Mild | 0.25 | 0.06 | 0.00 | 0.00 | 0.05 | 0.06 |
| Diarrhoea-non-SAE, NR, Moderate | 0.25 | 0.17 | 0.17 | 0.00 | 0.00 | 0.17 |
| Diarrhoea-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Diarrhoea Haemorrhagic-non-SAE, NR,Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Diarrhoea Infectious-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Diverticulitis-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Drug Eruption-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dyspnoea-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Dyspnoea-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ear Infection-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Ear Pain-non-SAE, NR, Mild | 0.00 | 0.06 | 0.17 | 0.00 | 0.03 | 0.06 |
| Ear Pain-non-SAE, R, Moderate | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.06 |
| Eczema-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.04 | 0.06 |
| Eczema-non-SAE, NR, Severe | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Epistaxis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Epistaxis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.14 | 0.00 | 0.07 | 0.10 |
| Excoriation-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.17 |
| Eye Infection Viral-non-SAE, NR, Moderate | 0.38 | 0.10 | 0.00 | 0.08 | 0.04 | 0.08 |
| Fall-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Fatigue-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.11 |
| Fatigue-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Fatigue-non-SAE, R, Mild | 0.25 | 0.17 | 0.00 | 0.17 | 0.00 | 0.22 |
| Fatigue-non-SAE, R, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Flank Pain-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fungal Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Furuncle-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.17 | 0.00 | 0.00 | 0.12 |
| Gastric Ulcer-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.09 |
| Gastric Ulcer-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Gastroenteritis-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Gastroenteritis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Gastroenteritis-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 0.20 | 0.06 | 0.00 | 0.00 | 0.00 | 0.06 |
| Gastroenteritis Viral-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.05 | 0.07 |
| Goitre-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gravitational Oedema-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Haematochezia-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Haemoglobin Decreased-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Haemorrhoids-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Head Injury-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Headache-non-SAE, NR, Mild | 0.25 | 0.13 | 0.17 | 0.08 | 0.04 | 0.07 |
| Headache-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.17 | 0.08 | 0.03 | 0.13 |
| Headache-non-SAE, NR, Severe | 0.00 | 0.00 | 0.17 | 0.00 | 0.07 | 0.12 |
| Headache-non-SAE, R, Mild | 1.10 | 0.23 | 0.17 | 0.17 | 0.11 | 0.18 |
| Headache-non-SAE, R, Moderate | 0.63 | 0.07 | 0.17 | 0.00 | 0.00 | 0.24 |
| Headache-non-SAE, R, Severe | 0.38 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Heart Rate Decreased-non-SAE, R, Mild | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.50 |
| Heart Rate Increased-non-SAE, NR, Mild | 0.00 | 0.25 | 0.00 | 0.08 | 0.00 | 0.17 |
| Heart Rate Increased-non-SAE, R, Mild | 0.25 | 0.08 | 0.25 | 0.08 | 0.03 | 0.08 |
| Heart Rate Increased-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hiatus Hernia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Hordeolum-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Hyperlipidaemia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Hypoxia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Implant Site Pain-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Infection-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Infection-non-SAE, NR, Moderate | 0.20 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Influenza-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.03 | 0.08 |
| Influenza-non-SAE, NR, Moderate | 0.20 | 0.07 | 0.00 | 0.00 | 0.04 | 0.06 |
| Infusion Related Reaction-non-SAE, R, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Erythema-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Haematoma-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.03 | 0.06 |
| Infusion Site Haematoma-non-SAE, R, Mild | 0.00 | 0.07 | 0.17 | 0.17 | 0.04 | 0.08 |
| Infusion Site Haematoma-non-SAE, R, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Infusion Site Haemorrhage-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Irritation-non-SAE, R, Mild | 0.25 | 0.10 | 0.00 | 0.00 | 0.05 | 0.07 |
| Infusion Site Oedema-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Pain-non-SAE, R, Mild | 0.20 | 0.14 | 0.15 | 0.08 | 0.04 | 0.16 |
| Infusion Site Pain-non-SAE, R, Moderate | 0.00 | 0.07 | 0.17 | 0.16 | 0.00 | 0.16 |
| Infusion Site Pruritus-non-SAE, NR, Moderate | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Infusion Site Pruritus-non-SAE, R, Mild | 0.00 | 0.07 | 0.17 | 0.08 | 0.00 | 0.08 |
| Infusion Site Pruritus-non-SAE, R, Moderate | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Infusion Site Rash-non-SAE, NR, Mild | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.06 |
| Infusion Site Rash-non-SAE, R, Mild | 0.00 | 0.08 | 0.17 | 0.00 | 0.03 | 0.08 |
| Infusion Site Reaction-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.09 |
| Infusion Site Swelling-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Swelling-non-SAE, R, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Infusion Site Vesicles-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Inguinal Mass-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Injection Site Haematoma-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Insomnia-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.03 | 0.03 |
| Insomnia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Intermit. Explosive Disorder-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Irritability-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.13 |
| Irritable Bowel Syndrome-non-SAE, NR, Moderate | 0.00 | 0.06 | 0.00 | 0.08 | 0.04 | 0.06 |
| Joint Dislocation-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Laryngitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Laryngitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Lethargy-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Limb Injury-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Lip Ulceration-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Livedo Reticularis-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Lung Infection-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Lung Infection-non-SAE, NR, Severe | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Lymphadenopathy-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Malaise-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Malaise-non-SAE, R, Moderate | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.10 |
| Middle Ear Effusion-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Migraine-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.03 | 0.06 |
| Migraine-non-SAE, NR, Severe | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Migraine-non-SAE, R, Severe | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Mouth Ulceration-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Muscular Weakness-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Musculoskeletal Chest Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.09 |
| Musculoskeletal Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Musculoskeletal Pain-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.07 | 0.04 | 0.07 |
| Myalgia-non-SAE, NR, Mild | 0.00 | 0.08 | 0.17 | 0.08 | 0.09 | 0.9 |
| Myalgia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Myopia-non-SAE, NR, Mild | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.10 |
| Nasal Congestion-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Nasal Congestion-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Nasal Disorder-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Nasal Mucosal Disorder-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Nasal Polyps-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Nasopharyngitis-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.08 | 0.04 | 0.05 |
| Nasopharyngitis-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.07 | 0.06 | 0.07 |
| Nausea-non-SAE, NR, Mild | 0.25 | 0.07 | 0.00 | 0.08 | 0.07 | 0.08 |
| Nausea-non-SAE, NR, Moderate | 0.00 | 0.07 | 0.00 | 0.17 | 0.03 | 0.07 |
| Nausea-non-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Nausea-non-SAE, R, Mild | 0.75 | 0.00 | 0.00 | 0.27 | 0.00 | 0.27 |
| Oedema Peripheral-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Oral Herpes-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.03 | 0.07 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.07 | 0.07 |
| Oropharyngeal Pain-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.07 | 0.08 |
| Osteomyelitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Otitis Externa-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Otitis Media-non-SAE, NR, Mild | 0.00 | 0.13 | 0.17 | 0.00 | 0.00 | 0.17 |
| Otitis Media-non-SAE, NR, Moderate | 0.00 | 0.17 | 0.00 | 0.13 | 0.11 | 0.14 |
| Pain-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pain In Extremity-non-SAE, NR, Mild | 0.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pain In Extremity-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Pain In Extremity-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Pain In Extremity-non-SAE, R, Severe | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Paraesthesia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Paronychia-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Periorbital Oedema-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Pharyngitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Pharyngitis-non-SAE, NR, Moderate | 0.50 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Pharyngitis Streptococcal-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Pneumonia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.04 | 0.06 |
| Pneumonia Streptococcal-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Procedural Pain-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.08 | 0.04 | 0.04 |
| Pyrexia-non-SAE, NR, Mild | 0.25 | 0.06 | 0.00 | 0.00 | 0.12 | 0.07 |
| Pyrexia-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Pyrexia-non-SAE, R, Mild | 0.63 | 0.17 | 0.00 | 0.00 | 0.07 | 0.07 |
| Pyrexia-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Rash-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Rash-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Rash Erythematous-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.05 | 0.07 |
| Rash Macular-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Rash Papular-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Rash Pruritic-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Respiratory Rate Increased-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Respir. Tract Infect. Viral-non-SAE, NR, Mild | 0.25 | 0.17 | 0.00 | 0.00 | 0.00 | 0.17 |
| Respir. Tract Infect Viral-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Rhinitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.09 |
| Rhinitis Allergic-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Rhinorrhoea-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Road Traffic Accident-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Scleritis-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Scleritis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Scoliosis-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Sinus Congestion-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Sinus Congestion-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Sinus Disorder-non-SAE, NR, Severe | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.06 |
| Sinus Headache-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Sinus Headache-non-SAE, NR, Moderate | 0.50 | 0.07 | 0.00 | 0.08 | 0.00 | 0.08 |
| Sinusitis-non-SAE, NR, Mild | 0.46 | 0.00 | 0.00 | 0.08 | 0.04 | 0.04 |
| Sinusitis-non-SAE, NR, Moderate | 0.25 | 0.07 | 0.17 | 0.08 | 0.04 | 0.08 |
| Sinusitis-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sinusitis Fungal-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Skin Laceration-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Skin Lesion-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Skin Papilloma-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Skin Warm-non-SAE, R, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Streptococcal Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Subcutaneous Abscess-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Suicidal Ideation-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sunburn-non-SAE, NR, Severe | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tendonitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tooth Fracture-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Tooth Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Toothache-non-SAE, NR, Moderate | 0.00 | 0.07 | 0.00 | 0.00 | 0.03 | 0.05 |
| Tourette's Disorder-non-SAE, NR, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Upper Respir. Tract Congestion-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Upper Respir. Tract Infection-non-SAE, NR, Mild | 0.23 | 0.08 | 0.17 | 0.08 | 0.06 | 0.08 |
| Upper Respir. Tract Infect.-non-SAE, NR, Moderate | 0.25 | 0.08 | 0.00 | 0.08 | 0.05 | 0.07 |
| Urinary Tract Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Urticaria-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Urticaria-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Vaginal Lesion-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Vaginitis Bacterial-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Varicose Vein-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Varicose Vein-non-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Viral Infection-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Viral Infection-non-SAE, NR, Moderate | 0.38 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Viral Skin Infection-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Viral Upper Respir. Tract Infect-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Vitamin D Deficiency-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Vomiting-non-SAE, NR, Mild | 0.25 | 0.07 | 0.17 | 0.08 | 0.04 | 0.07 |
| Vomiting-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Vomiting-non-SAE, R, Mild | 0.75 | 0.00 | 0.00 | 0.09 | 0.05 | 0.07 |
| Vomiting-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.18 | 0.00 | 0.18 |
| Vulvovaginal Candidiasis-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Vulvovaginal Mycotic Infection-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Wheezing-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.09 |
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR
| Adverse events | Study Part 1, IV Administration | Study Part 2, SC Administration | Study Part 3a, SC Administration | Study Part 3b, SC Administration | Study Extension, SC Administration | Total SC (Parts 2, 3a, 3b, Extension) |
|---|---|---|---|---|---|---|
| Abdominal Discomfort- non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Abdominal Distension-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 7 | 7 |
| Abdominal Distension-non-SAE, NR, Moderate | 0 | 0 | 0 | 2 | 2 | 4 |
| Abdominal Distension-non-SAE, R, Mild | 0 | 1 | 0 | 1 | 0 | 2 |
| Abdominal Distension-non-SAE, R, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Abdominal Pain-non-SAE, NR, Mild | 1 | 0 | 1 | 0 | 0 | 1 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 4 | 4 |
| Abdominal Pain Upper-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 2 | 2 |
| Abdominal Pain Upper-non-SAE, R, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Abdominal Tenderness-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Acne-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Addison's Disease-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Addison's Disease-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Arthralgia-non-SAE, NR, Moderate | 0 | 1 | 1 | 2 | 1 | 5 |
| Arthralgia-non-SAE, NR, Severe | 0 | 0 | 0 | 0 | 1 | 1 |
| Asthenia-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Back Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Back Pain-non-SAE, NR, Moderate | 0 | 0 | 0 | 2 | 0 | 2 |
| Blepharitis-non-SAE,NR, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Breath Sounds Abnormal-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Bronchitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 2 | 2 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Chronic Sinusitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Conjunctivitis Bacterial-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Conjunctivitis Infective-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Costochondritis-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Costochondritis-non-SAE, NR, Severe | 0 | 1 | 0 | 0 | 0 | 1 |
| Cough-non-SAE, NR, Mild | 2 | 0 | 0 | 0 | 0 | 0 |
| Cystitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Dermatitis-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Dermatitis Contact-non-SAE, NR, Moderate | 1 | 1 | 0 | 1 | 0 | 2 |
| Diarrhoea-non-SAE, NR, Mild | 0 | 1 | 0 | 2 | 1 | 4 |
| Diarrhoea-non-SAE, NR, Moderate | 1 | 0 | 0 | 1 | 0 | 1 |
| Diarrhoea-non-SAE, R, Mild | 0 | 0 | 2 | 0 | 0 | 2 |
| Dyspepsia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Dyspnoea-non-SAE, NR, Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Ear Pain-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 1 | 1 |
| Exostosis-non-SAE, NR,Mild | 0 | 0 | 1 | 0 | 0 | 1 |
| Eye Infection Viral-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Eye Irritation-non-SAE, R, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Eye Oedema-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Fatigue-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Flatulence-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Flatulence-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Folliculitis-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Headache-non-SAE, NR, Mild | 1 | 2 | 1 | 1 | 0 | 4 |
| Headache-non-SAE, R, Mild | 0 | 2 | 0 | 0 | 0 | 2 |
| Infection-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 1 | 2 |
| Influenza-non-SAE, NR, Moderate | 1 | 0 | 0 | 1 | 0 | 1 |
| Infusion Site Haematoma-non-SAE, R, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Infusion Site Haemorrhage-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Oedema-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Pain-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Infusion Site Pruritus-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Injection Site Haematoma-non-SAE, R, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Injection Site Pain-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Joint Sprain-non-SAE, NR, Mild | 0 | 2 | 0 | 0 | 0 | 2 |
| Joint Swelling-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Joint Swelling-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Laryngitis Viral-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Limb Injury-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphadenopathy-non-SAE, NR, Mild | 1 | 0 | 1 | 0 | 0 | 1 |
| Memory Impairment-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Migraine-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Migraine-non-SAE, R, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Muscle Strain-non-SAE, NR, Mild | 0 | 0 | 1 | 0 | 1 | 2 |
| Nasal Congestion-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Nasal Congestion-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Nasopharyngitis-non-SAE, NR, Mild | 2 | 1 | 0 | 0 | 2 | 3 |
| Nasopharyngitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 2 | 2 |
| Nausea-non-SAE, NR, Mild | 0 | 1 | 1 | 1 | 4 | 7 |
| Nausea-non-SAE, R, Mild | 0 | 1 | 1 | 0 | 1 | 3 |
| Nausea-non-SAE, R, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Oedema Peripheral-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Oral Herpes-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Oropharyngeal Pain-non-SAE, NR, Moderate | 2 | 0 | 0 | 0 | 1 | 1 |
| Osteopenia-non-SAE, NR, Moderate | 0 | 1 | 0 | 0 | 0 | 1 |
| Pain In Extremity-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 0 | 1 |
| Pharyngitis-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Pharyngitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Pneumonia-non-SAE, NR, Mild | 0 | 0 | 0 | 1 | 0 | 1 |
| Pneumonia Bacterial-non-SAE, NR, Moderate | 0 | 0 | 1 | 0 | 0 | 1 |
| Pyrexia-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 1 | 2 |
| Rales-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Respir. Tract Infect. Viral-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Respir. Tract Infect Viral-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Sinusitis-non-SAE, NR, Mild | 0 | 0 | 0 | 0 | 1 | 1 |
| Sinusitis-non-SAE, NR, Moderate | 1 | 0 | 2 | 1 | 0 | 3 |
| Sports Injury-non-SAE, NR, Mild | 0 | 1 | 0 | 0 | 0 | 1 |
| Upper Respir. Tract Infection-non-SAE, NR, Mild | 2 | 0 | 0 | 1 | 1 | 2 |
| Upper Respir. Tract Infect.-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Urinary Tract Infection-non-SAE, NR, Moderate | 1 | 0 | 0 | 0 | 0 | 0 |
| Vestibulitis-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Viral Up. Respir Tract Infec-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
| Vomiting-non-SAE, NR, Mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Vulvovaginal Mycotic Infect.-non-SAE, NR, Moderate | 0 | 0 | 0 | 0 | 1 | 1 |
| Wound-non-SAE, NR, Moderate | 0 | 0 | 0 | 1 | 0 | 1 |
Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.
| AEs per infusion | Study Part 1, IV Administration | Study Part 2, SC Administration | Study Part 3a, SC Administration | Study Part 3b, SC Administration | Study Extension, SC Administration | Total SC (Parts 2, 3a, 3b, Extension) |
|---|---|---|---|---|---|---|
| Abdominal Discomfort- non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Abdominal Distension-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.29 |
| Abdominal Distension-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.17 | 0.08 | 0.13 |
| Abdominal Distension-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Abdominal Distension-non-SAE, R, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Abdominal Pain-non-SAE, NR, Mild | 0.25 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.17 |
| Abdominal Pain Upper-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 |
| Abdominal Pain Upper-non-SAE, R, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Abdominal Tenderness-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Acne-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Addison's Disease-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Addison's Disease-non-SAE, NR, Moderate | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Arthralgia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.17 | 0.17 | 0.04 | 0.13 |
| Arthralgia-non-SAE, NR, Severe | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Asthenia-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Back Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Back Pain-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.17 |
| Blepharitis-non-SAE,NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Breath Sounds Abnormal-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Bronchitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Chronic Sinusitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Conjunctivitis Bacterial-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Conjunctivitis Infective-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Costochondritis-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Costochondritis-non-SAE, NR, Severe | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Cough-non-SAE, NR, Mild | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cystitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Dermatitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dermatitis Contact-non-SAE, NR, Moderate | 0.25 | 0.08 | 0.00 | 0.08 | 0.00 | 0.08 |
| Diarrhoea-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.17 | 0.04 | 0.08 |
| Diarrhoea-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Diarrhoea-non-SAE, R, Mild | 0.00 | 0.00 | 0.33 | 0.00 | 0.00 | 0.33 |
| Dyspepsia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Dyspnoea-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Ear Pain-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Exostosis-non-SAE, NR,Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Eye Infection Viral-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Eye Irritation-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Eye Oedema-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Fatigue-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Flatulence-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Flatulence-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Folliculitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Headache-non-SAE, NR, Mild | 0.20 | 0.17 | 0.17 | 0.08 | 0.00 | 0.17 |
| Headache-non-SAE, R, Mild | 0.00 | 0.16 | 0.00 | 0.00 | 0.00 | 0.16 |
| Infection-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.04 | 0.10 |
| Influenza-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Infusion Site Haematoma-non-SAE, R, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Infusion Site Haemorrhage-non-SAE, R, Mild | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.07 |
| Infusion Site Oedema-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Infusion Site Pain-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Infusion Site Pruritus-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Injection Site Haematoma-non-SAE, R, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Injection Site Pain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Joint Sprain-non-SAE, NR, Mild | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.17 |
| Joint Swelling-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Joint Swelling-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Laryngitis Viral-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Limb Injury-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Lymphadenopathy-non-SAE, NR, Mild | 0.25 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Memory Impairment-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Migraine-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Migraine-non-SAE, R, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Muscle Strain-non-SAE, NR, Mild | 0.00 | 0.00 | 0.17 | 0.00 | 0.03 | 0.10 |
| Nasal Congestion-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Nasal Congestion-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Nasopharyngitis-non-SAE, NR, Mild | 0.25 | 0.08 | 0.00 | 0.00 | 0.04 | 0.04 |
| Nasopharyngitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 |
| Nausea-non-SAE, NR, Mild | 0.00 | 0.08 | 0.17 | 0.08 | 0.17 | 0.13 |
| Nausea-non-SAE, R, Mild | 0.00 | 0.08 | 0.17 | 0.00 | 0.04 | 0.08 |
| Nausea-non-SAE, R, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Oedema Peripheral-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Oral Herpes-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Oropharyngeal Pain-non-SAE, NR, Moderate | 0.23 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Osteopenia-non-SAE, NR, Moderate | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Pain In Extremity-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Pharyngitis-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Pharyngitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Pneumonia-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Pneumonia Bacterial-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.17 |
| Pyrexia-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.04 | 0.06 |
| Rales-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Respir. Tract Infect. Viral-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Respir. Tract Infect Viral-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sinusitis-non-SAE, NR, Mild | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 |
| Sinusitis-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.17 | 0.08 | 0.00 | 0.17 |
| Sports Injury-non-SAE, NR, Mild | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.08 |
| Upper Respir. Tract Infection-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.08 | 0.03 | 0.06 |
| Upper Respir. Tract Infect.-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Urinary Tract Infection-non-SAE, NR, Moderate | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Vestibulitis-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Viral Up. Respir Tract Infec-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Vomiting-non-SAE, NR, Mild | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Vulvovaginal Mycotic Infect.-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 |
| Wound-non-SAE, NR, Moderate | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
| Percentage of infusions | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) (Units Analyzed N= 207, 162, 45) | 22.2 | 27.8 | 2.2 |
| Study Part 2 (SC) (N = 595, 469, 126) | 9.9 | 10.2 | 8.7 |
| Study Part 3a (SC) (N = 268, 206, 62) | 7.8 | 8.3 | 6.5 |
| Study Part 3b (SC) (N = 538, 418, 120) | 3.5 | 4.3 | 0.8 |
| Study Extension (SC) (N = 893, 664, 229) | 3.1 | 3.8 | 1.3 |
| Total SC (N = 2294, 1757, 537) | 5.5 | 6.1 | 3.5 |
| Percentage of infusions | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) (Units Analyzed N= 207, 162, 45) | 30.9 | 35.8 | 13.3 |
| Study Part 2 (SC) (N = 595, 469, 126) | 15.0 | 15.8 | 11.9 |
| Study Part 3a (SC) (N = 268, 206, 62) | 11.6 | 12.6 | 8.1 |
| Study Part 3b (SC) (N = 538, 418, 120) | 8.7 | 8.9 | 8.3 |
| Study Extension (SC) (N = 893, 664, 229) | 9.4 | 10.5 | 6.1 |
| Total SC (N = 2294, 1757, 537) | 10.9 | 11.8 | 8.2 |
| Percentage of infusions | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) (Units Analyzed N= 207, 162, 45) | 28.5 | 32.7 | 13.3 |
| Study Part 2 (SC) (N = 595, 469, 126) | 11.8 | 12.2 | 10.3 |
| Study Part 3a (SC) (N = 268, 206, 62) | 10.1 | 11.2 | 6.5 |
| Study Part 3b (SC) (N = 538, 418, 120) | 7.2 | 7.2 | 7.5 |
| Study Extension (SC) (N = 893, 664, 229) | 7.3 | 8.1 | 4.8 |
| Total SC (N = 2294, 1757, 537) | 8.8 | 9.3 | 6.9 |
| Percentage of infusions | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) (Units Analyzed N= 207, 162, 45) | 28.0 | 32.1 | 13.3 |
| Study Part 2 (SC) (N = 595, 469, 126) | 7.6 | 7.7 | 7.1 |
| Study Part 3a (SC) (N = 268, 206, 62) | 7.8 | 8.3 | 6.5 |
| Study Part 3b (SC) (N = 538, 418, 120) | 6.1 | 5.7 | 7.5 |
| Study Extension (SC) (N = 893, 664, 229) | 6.3 | 6.9 | 4.4 |
| Total SC (N = 2294, 1757, 537) | 6.8 | 7.0 | 6.0 |
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
| Percentage of Participants | Infusion Rate Change - For Any Reason | Infusion Rate Change - For Tolerability/AE |
|---|---|---|
| Study Part 1 (IV) (n= 11) | 0.0 | 0.00 |
| Study Part 2 (SC) (n= 11) | 18.2 | 0.00 |
| Study Part 3A (SC) (n=10) | 0.00 | 0.00 |
| Study Part 3B (SC) (n=10) | 0.00 | 0.00 |
| Study Extension (SC) (n= 9) | 11.1 | 0.00 |
| Study Part 2, 3A, 3B, Study Extension (n= 11) | 18.2 | 0.00 |
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
| Percentage of Infusions | Infusion Rate Change (Percentage) - For Any Reason | Infusion Rate Change - For Tolerability/AE |
|---|---|---|
| Study Part 1 (IV) (n= 207 Infusions) | 6.7 (3.6 to 11.3) | 6.2 (3.2 to 10.5) |
| Study Part 2 (SC) (n= 595 Infusions) | 4.2 (2.7 to 6.2) | 0.5 (0.1 to 1.3) |
| Study Part 3A (SC) (n=268 Infusions) | 3.1 (1.4 to 5.8) | 0.4 (0.0 to 1.7) |
| Study Part 3B (SC) (n=538 Infusions) | 1.1 (0.4 to 2.3) | 0.2 (0.0 to 0.8) |
| Study Extension (SC) (n= 893 Infusions) | 0.6 (0.2 to 1.2) | 0.0 (NA to NA) |
| Parts 2, 3A, 3B, & Extension (n= 2,294 Infusions) | 1.9 (1.4 to 2.5) | 0.2 (0.1 to 0.5) |
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
| Percentage of Infusions | Infusion Rate Change (Percentage) - For Any Reason | Infusion Rate Change - For Tolerability/AE |
|---|---|---|
| Study Part 1 (IV) (n= 162 Infusions) | 8.7 (4.7 to 14.8) | 8.0 (4.2 to 13.8) |
| Study Part 2 (SC) (n= 469 Infusions) | 4.5 (2.8 to 6.8) | 0.6 (0.2 to 1.7) |
| Study Part 3A (SC) (n=206 Infusions) | 4.0 (1.8 to 7.7) | 0.5 (0.0 to 2.2) |
| Study Part 3B (SC) (n=418 Infusions) | 1.5 (0.6 to 3.0) | 0.2 (0.0 to 1.1) |
| Study Extension (SC) (n= 664 Infusions) | 0.6 (0.2 to 1.4) | 0.0 (NA to NA) |
| Parts 2, 3A, 3B, & Extension (n= 1,757 Infusions) | 2.2 (1.6 to 3.0) | 0.3 (0.1 to 0.6) |
Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs
| Percentage of Infusions | Infusion Rate Change (Percentage) - For Any Reason | Infusion Rate Change - For Tolerability/AE |
|---|---|---|
| Study Part 1 (IV) (n= 45 Infusions) | 0.0 (NA to NA) | 0.0 (NA to NA) |
| Study Part 2 (SC) (n= 126 Infusions) | 3.3 (1.0 to 7.8) | 0.0 (NA to NA) |
| Study Part 3A (SC) (n=62 Infusions) | 0.0 (NA to NA) | 0.0 (NA to NA) |
| Study Part 3B (SC) (n=120 Infusions) | 0.0 (NA to NA) | 0.0 (NA to NA) |
| Study Extension (SC) (n= 229 Infusions) | 0.4 (0.0 to 1.9) | 0.0 (NA to NA) |
| Parts 2, 3A, 3B, & Extension (n= 537 Infusions) | 0.9 (0.3 to 2.0) | 0.0 (NA to NA) |
| Percentage of infusions | FSDS | SNSC | SESC |
|---|---|---|---|
| Study Part 1 (IV) (Units Analyzed N= 207, 162, 45) | 1.0 | 1.2 | 0.0 |
| Study Part 2 (SC) (N = 595, 469, 126) | 4.9 | 5.1 | 4.0 |
| Study Part 3a (SC) (N = 268, 206, 62) | 2.2 | 2.9 | 0.0 |
| Study Part 3b (SC) (N = 538, 418, 120) | 1.5 | 1.9 | 0.0 |
| Study Extension (SC) (N = 893, 664, 229) | 1.1 | 1.4 | 0.4 |
| Total SC (N = 2294, 1757, 537) | 2.3 | 2.7 | 1.1 |
Collected over Throughout the entire study period (1 year, 9 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Treatment Period | — | 2/49 (4.1%) | 38/49 (77.6%) |
| SC Treatment Period | — | 2/48 (4.2%) | 44/47 (93.6%) |
| Event | IV Treatment Period | SC Treatment Period |
|---|---|---|
| Biliary Tract Infection BacterialInfections and infestations | 0/49 | 1/48 |
| Chest painGeneral disorders | 0/49 | 1/48 |
| SinusitisInfections and infestations | 1/49 | 0/48 |
| Convulsion/seizureNervous system disorders | 1/49 | 0/48 |
| Event | IV Treatment Period | SC Treatment Period |
|---|---|---|
| HEADACHENervous system disorders | 17/49 | 23/47 |
| PYREXIAGeneral disorders | 5/49 | 14/47 |
| INFUSION SITE PAINGeneral disorders | 1/49 | 10/47 |
| NAUSEAGastrointestinal disorders | 5/49 | 8/47 |
| VOMITINGGastrointestinal disorders | 7/49 | 7/47 |
| FATIGUEGeneral disorders | 1/49 | 7/47 |
| CHILLSGeneral disorders | 7/49 | 0/47 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 3/49 | 6/47 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 1/49 | 6/47 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 1/49 | 5/47 |
| Age, Customized(Participants) | Treated Participants |
|---|---|
| 2 to <12 years | 14 |
| ≥ 12 years | 35 |
| Sex: Female, Male(Participants) | Treated Participants |
|---|---|
| Female | 22 |
| Male | 27 |
| Region of Enrollment(Participants) | Treated Participants |
|---|---|
| United States | 49 |
Ran from Oct 2007 to primary completion in Jul 2009, 20 months.
Results were first posted in Aug 2012, 3 years 1 month after primary completion. A results delay was requested in Jul 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Primary Immunodeficiency Diseases →